

1 **Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-**
2 **19 and Cancer Consortium (CCC19) Cohort Study**

3
4 **BRIEF TITLE: COVID-19 and Breast Cancer**

5 **AUTHORS:** Gayathri Nagaraj, MD^{1*#}; Shaveta Vinayak, MD, MS^{2,3,4*}; Ali Raza Khaki, MD^{5*}; Tianyi Sun, MS⁶; Nicole M.
6 Kuderer, MD^{3,7}; David M. Aboulaflia, MD⁸; Jared D. Acoba, MD⁹; Joy Awosika, MD¹⁰; Ziad Bakouny, MD, MSc¹¹; Nicole
7 B. Balmaceda, MD¹²; Ting Bao, MD, DABMA, MS¹³; Babar Bashir, MD, MS¹⁴; Stephanie Berg, DO¹⁵; Mehmet A. Bilen,
8 MD¹⁶; Poorva Bindal, MD¹⁷; Sibel Blau, MD¹⁸; Brianne E. Bodin, BS¹⁹; Hala T. Borno, MD²⁰; Cecilia Castellano, BA¹⁶;
9 Horyun Choi, MD⁹; John Deeken, MD²¹; Aakash Desai, MD, MPH²²; Natasha Edwin, MD²³; Lawrence E. Feldman, MD²⁴;
10 Daniel B. Flora, MD, PharmD²⁵; Christopher R. Friese, PhD, RN²⁶; Matthew D. Galsky, MD²⁷; Cyndi J. Gonzalez, BS²⁶;
11 Petros Grivas, MD, PhD^{2,3,4}; Shilpa Gupta, MD²⁸; Marcy Haynam, MS²⁹; Hannah Heilman, BS¹⁰; Dawn L. Hershman, MD,
12 MS¹⁹; Clara Hwang, MD³⁰; Chinmay Jani, MD³¹; Sachin R. Jhawar, MD²⁹; Monika Joshi, MD³²; Virginia Kaklamani, MD,
13 DSc³³; Elizabeth J. Klein, BA³⁴; Natalie Knox, BS³⁵; Vadim S. Koshkin, MD²⁰; Amit A. Kulkarni, MD³⁶; Daniel H. Kwon,
14 MD²⁰; Chris Labaki, MD¹¹; Philip E. Lammers, MD, MSCI³⁷; Kate I. Lathrop, MD³³; Mark A. Lewis, MD³⁸; Xuanyi Li,
15 MD⁶; Gilberto de Lima Lopes, MD, MBA³⁹; Gary H. Lyman, MD, MPH^{2,3,4}; Della F. Makower, MD⁴⁰; Abdul-Hai Mansoor,
16 MD⁴¹; Merry-Jennifer Markham, MD⁴²; Sandeep H. Mashru, MD⁴¹; Rana R. McKay, MD⁴³; Ian Messing, MST⁴⁴; Vasil
17 Mico, BS¹⁴; Rajani Nadkarni, MD⁴⁵; Swathi Namburi, MD¹⁸; Ryan H. Nguyen, DO²⁴; Taylor Kristian Nonato, BS⁴³; Tracey
18 Lynn O'Connor, MD⁴⁶; Orestis A. Panagiotou, MD, PhD³⁴; Kyu Park, BA¹; Jaymin M. Patel, MD¹⁷; Kanishka GopikaBimal
19 Patel, MD⁴⁷; Jeffrey Peppercorn, MD⁴⁸; Hyma Polimera, MD³²; Matthew Puc, MD⁴⁹; Yuan James Rao, MD⁴⁴; Pedram
20 Razavi, BS⁴³; Sonya A. Reid, MBBS; MPH⁶; Jonathan W. Riess, MD, MS⁴⁷; Donna R. Rivera, DPharm, MSc⁵⁰; Mark
21 Robson, MD¹³; Suzanne J. Rose, MS, PhD⁵¹; Atlantis D. Russ, MD, PhD⁴²; Lidia Schapira, MD⁵; Pankil K. Shah, MD,
22 MSPH³³; M. Kelly Shanahan, MD⁵²; Lauren C. Shapiro, MD⁴⁰; Melissa Smits, APNP²³; Daniel G. Stover, MD²⁹; Mitrianna
23 Streckfuss, MPH, CCRP⁵³; Lisa Tachiki, MD^{2,3,4}; Michael A. Thompson, MD, PhD⁵³; Sara M. Tolaney, MD, MPH¹¹; Lisa B.
24 Weissmann, MD³¹; Grace Wilson, BA³⁶; Michael T. Wotman, MD²⁷; Elizabeth M. Wulff-Burchfield, MD¹²; Sanjay Mishra,
25 MS, PhD⁶; Benjamin French, PhD⁶; Jeremy L. Warner, MD, MS⁶; Maryam B. Lustberg, MD, MPH^{54**}; Melissa K.
26 Accordino, MD, MS^{19**}; Dimpy P. Shah, MD, PhD^{33**} on behalf of the COVID-19 and Cancer Consortium.

27

Formatted: Numbering: Continuous

28 **AFFILIATIONS:**

29 ¹Loma Linda University Cancer Center, Loma Linda, CA

30 ²Fred Hutchinson Cancer Research Center, Seattle, WA

31 ³University of Washington, Seattle, WA

32 ⁴Seattle Cancer Care Alliance, Seattle, WA

33 ⁵Stanford University, Palo Alto, CA

34 ⁶Vanderbilt University Medical Center, Nashville, TN

35 ⁷Advanced Cancer Research Group, Kirkland, WA

36 ⁸Virginia Mason Cancer Institute, Seattle, WA

37 ⁹University of Hawaii Cancer Center, Honolulu, HI

38 ¹⁰University of Cincinnati Cancer Center, Cincinnati, OH

39 ¹¹Dana-Farber Cancer Institute, Boston, MA

40 ¹²The University of Kansas Cancer Center, Kansas City, KS

41 ¹³Memorial Sloan-Kettering Cancer Center, New York, NY

42 ¹⁴Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA

43 ¹⁵Loyola University Medical Center, Maywood, IL

44 ¹⁶Winship Cancer Institute of Emory University, Atlanta, GA

45 ¹⁷Beth Israel Deaconess Medical Center, Boston, MA

46 ¹⁸Northwest Medical Specialties, Tacoma, WA

47 ¹⁹Herbert Irving Comprehensive Cancer Center at Columbia University, New York, NY

48 ²⁰UCSF Helen Diller Family Comprehensive Cancer Center at the University of California at San Francisco, San Francisco,

49 CA

50 ²¹Inova Schar Cancer Institute, Fairfax, VA

51 ²²Mayo Clinic, MN

52 ²³ThedaCare Cancer Care, Appleton, WI

53 ²⁴University of Illinois Hospital & Health Sciences System, Chicago, IL

54 ²⁵St. Elizabeth Healthcare, Edgewood, KY

55 ²⁶University of Michigan Rogel Cancer Center, Ann Arbor, MI

- 56 ²⁷Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, New York, NY
- 57 ²⁸Cleveland Clinic, Cleveland, OH
- 58 ²⁹The Ohio State University Comprehensive Cancer Center, Columbus, OH
- 59 ³⁰Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, MI
- 60 ³¹Mount Auburn Hospital, Cambridge, MA
- 61 ³²Penn State Health St. Joseph Cancer Center, PA
- 62 ³³Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
- 63 ³⁴Brown University and Lifespan Cancer Institute, Providence, RI
- 64 ³⁵Stritch School of Medicine at Loyola University, Maywood, IL
- 65 ³⁶Masonic Cancer Center at the University of Minnesota, Minneapolis, MN
- 66 ³⁷Baptist Cancer Center, Memphis, TN
- 67 ³⁸Intermountain Health Care, Salt Lake City, UT
- 68 ³⁹Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL
- 69 ⁴⁰Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY
- 70 ⁴¹Kaiser Permanente Northwest, OR/WA
- 71 ⁴²University of Florida, Division of Hematology and Oncology, UF Health Cancer Center, Gainesville, FL
- 72 ⁴³Moore's Cancer Center, University of California, San Diego, CA
- 73 ⁴⁴Division of Radiation Oncology, George Washington University, Washington, DC
- 74 ⁴⁵Hartford HealthCare Cancer Institute, Hartford, CT
- 75 ⁴⁶Roswell Park Comprehensive Cancer Center, Buffalo, NY
- 76 ⁴⁷UC Davis Comprehensive Cancer Center at the University of California at Davis, CA
- 77 ⁴⁸Massachusetts General Hospital, Boston, MA
- 78 ⁴⁹Virtua Health, Marlton, NJ
- 79 ⁵⁰Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, USA
- 80 ⁵¹Carl & Dorothy Bennett Cancer Center at Stamford Hospital, Stamford, CT
- 81 ⁵²METAvisor
- 82 ⁵³Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI
- 83 ⁵⁴Yale Cancer Center at Yale University School of Medicine, New Haven, CT

84 *Co-Primary authors

85 **Co-Senior authors

86

87 **CORRESPONDING AUTHORS:**

88 Gayathri Nagaraj MD, Division of Medical Oncology and Hematology, Loma Linda University School of Medicine, 11175

89 Campus Street, CSP 11015, Loma Linda, CA 92354. Ph: 909-558-4910; Email: gnagaraj@llu.edu

90 Dimpy P. Shah, MD, PhD, Population Health Sciences, Mays Cancer Center at UTHealth San Antonio MD Anderson, 7703

91 Floyd Curl Drive, San Antonio, TX, 78229, Ph: 210-562-6503; Email: ShahDP@uthscsa.edu

92

93 **KEYWORDS:** Breast cancer, SARS-CoV-2, COVID-19, Risk Factors, Racial Inequities, Oncology, Pandemic,

94

95 **WORD COUNT:** 3477

96

97

98

99

100

101

102

103

104

105

106 **ABSTRACT**

107 **Background:** Limited information is available for patients with breast cancer (BC) and coronavirus disease 2019 (COVID-
108 19), especially among underrepresented racial/ethnic populations.

109 **Methods:** This is a COVID-19 and Cancer Consortium (CCC19) registry-based retrospective cohort study of females with
110 active or history of BC and laboratory-confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection
111 diagnosed between March 2020 and June 2021 in the US. Primary outcome was COVID-19 severity measured on a five-level
112 ordinal scale, including none of the following complications, hospitalization, intensive care unit admission, mechanical
113 ventilation, and all-cause mortality. Multivariable ordinal logistic regression model identified characteristics associated with
114 COVID-19 severity.

115 **Results:** 1,383 female patient records with BC and COVID-19 were included in the analysis, the median age was 61 years,
116 and median follow-up was 90 days. Multivariable analysis revealed higher odds of COVID-19 severity for older age (aOR
117 per decade, 1.48 [95% CI, 1.32 – 1.67]); Black patients (aOR 1.74; 95 CI 1.24-2.45), Asian Americans and Pacific Islander
118 patients (aOR 3.40; 95 CI 1.70 – 6.79) and Other (aOR 2.97; 95 CI 1.71-5.17) racial/ethnic groups; worse ECOG
119 performance status (ECOG PS \geq 2: aOR, 7.78 [95% CI, 4.83 – 12.5]); pre-existing cardiovascular (aOR, 2.26 [95% CI, 1.63 –
120 3.15])/pulmonary comorbidities (aOR, 1.65 [95% CI, 1.20 – 2.29]); diabetes mellitus (aOR, 2.25 [95% CI, 1.66 – 3.04]); and
121 active and progressing cancer (aOR, 12.5 [95% CI, 6.89 – 22.6]). Hispanic ethnicity, timing and type of anti-cancer therapy
122 modalities were not significantly associated with worse COVID-19 outcomes. The total all-cause mortality and
123 hospitalization rate for the entire cohort was 9% and 37%, respectively however, it varied according to the BC disease status.

124 **Conclusions:** Using one of the largest registries on cancer and COVID-19, we identified patient and BC related factors
125 associated with worse COVID-19 outcomes. After adjusting for baseline characteristics, underrepresented racial/ethnic
126 patients experienced worse outcomes compared to Non-Hispanic White patients.

127 **Funding:** This study was partly supported by National Cancer Institute grant number P30 CA068485 to Tianyi Sun, Sanjay
128 Mishra, Benjamin French, Jeremy L. Warner; P30-CA046592 to Christopher R. Friese; P30 CA023100 for Rana R McKay;
129 P30-CA054174 for Pankil K. Shah and Dimpy P. Shah; and the American Cancer Society and Hope Foundation for Cancer
130 Research (MRSG-16-152-01 -CCE) and P30-CA054174 for Dimpy P. Shah. REDCap is developed and supported by

131 Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding
132 sources had no role in the writing of the manuscript or the decision to submit it for publication.

133 **Clinical Trial Number:** CCC19 registry is registered on ClinicalTrials.gov, NCT04354701.

134

135

136 **ABBREVIATIONS:**

137 CCC19: Cancer and COVID-19 Consortium

138 COVID-19: Coronavirus disease 2019

139 BC: Breast Cancer

140 SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2

141 NHW: Non-Hispanic White

142 AAPI: Asian Americans and Pacific Islanders

143 ECOG PS: Eastern Cooperative Oncology Group performance status

144 HR: Hormone receptor

145 HER2: Human epidermal growth factor receptor 2

146 CDK 4/6 inhibitor: Cyclin-dependent kinase 4/6 inhibitor

147 NED: No evidence of disease

148 MBC: Metastatic breast cancer

149

150

151

152

153

154

155

156

157 **INTRODUCTION**

158 The COVID-19 pandemic has had a devastating impact worldwide and within the United States (U.S.).[1], [2] Previous
159 studies have reported that patients with cancer are at an increased risk for SARS-CoV-2 infection and have higher rates of
160 adverse outcomes with mortality rates ranging from 14% to 33%.[3]–[10] COVID-19 has also highlighted the long-standing
161 health inequities in the U.S, as underrepresented racial and ethnic populations have disproportionately been affected. Some
162 studies have reported non-White race/ethnicity to be an independent risk factor for worse COVID-19 outcomes such as
163 hospitalization and death.[3], [6], [11]–[20] Recently published data from CCC19 also showed that Black patients with
164 cancer experienced worse COVID-19 outcomes compared to White patients after adjusting for key risk factors including
165 cancer status and comorbidities.[21]

166
167 Breast cancer (BC) is the most common cancer diagnosed in females and affects all major racial/ethnic groups.[22]–[24]
168 There are well described racial/ethnic differences in BC incidence and outcomes in females in the U.S attributable to multiple
169 social and biological factors.[25]–[27] Few studies have specifically evaluated the impact of COVID-19 in patients with BC;
170 interpretation from prior studies has been limited by small sample sizes.[28], [29] Data specifically on the impact of COVID-
171 19 among underrepresented racial/ethnic groups with BC are also lacking. Understanding the sociodemographic and clinical
172 factors associated with higher risk for adverse COVID-19 outcomes will help guide patient care. Hence, we aimed to evaluate
173 the prognostic factors, racial disparities, interventions, complications, and outcomes among patients with active or previous
174 history of BC diagnosed with COVID-19.

175

176 **METHODS**

177 **Study population**

178 The COVID-19 and Cancer Consortium (CCC19) consists of 129 member institutions capturing granular, detailed, and
179 uniform data on demographic and clinical characteristics, treatment information, and outcomes of COVID-19. Details of
180 CCC19 protocol, data collection, and quality assurance have been previously described.[30], [31] This registry-based
181 retrospective cohort study included all female adults (age \geq 18 years) with an active or previous history of invasive BC and
182 laboratory-confirmed diagnosis of SARS-CoV-2 by polymerase chain reaction (PCR) and/or serology from March 17, 2020,
183 to June 16, 2021 in the United States. Patient records with multiple invasive malignancies including history of multiple

184 invasive BC were excluded; patients with unknown or missing race and ethnicity, inadequate data quality (quality score>4)
185 and those not evaluable for the primary ordinal outcome were also excluded (*supplementary appendix*).[31] This study was
186 exempt from institutional review board (IRB) review (VUMC IRB#200467) and was approved by IRBs at participating sites
187 per institutional policy. CCC19 registry is registered on ClinicalTrials.gov, NCT04354701.

188

189 **Outcome definitions**

190 The primary outcome was a five-level ordinal scale of COVID-19 severity based on each individual patient's most severe
191 reported disease status: none of the following complications (0); admitted to the hospital; admitted to an intensive care unit
192 (ICU); mechanically ventilated at any time after COVID-19 diagnosis; or death from any cause. Other COVID-19 related
193 complications (cardiovascular; gastrointestinal; and pulmonary complications, acute kidney injury, multisystem organ failure,
194 superimposed infection, sepsis, any bleeding); 30-day mortality; and anti-COVID-19 directed interventions (supplemental
195 oxygen, remdesivir, systemic corticosteroids, hydroxychloroquine, and other treatments) are also reported.

196

197 **Covariates**

198 Covariates were selected *a priori* and included: age; sex; race/ethnicity (Non-Hispanic White [NHW], Black, Hispanic, Asian
199 Americans and Pacific Islanders [AAPI], and Other) as recorded in the EHR, based on the Center for Disease Control and
200 Prevention Race and Ethnicity codes[32]; U.S census region of reporting institution (Northeast [NE], Midwest [MW], South
201 and West); month/year of COVID-19 diagnosis (classified into 4-month intervals); smoking status; obesity; comorbidities
202 (cardiovascular, pulmonary, renal, or diabetes mellitus); Eastern Cooperative Oncology Group (ECOG) performance status
203 (PS); BC subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression
204 (HR+/HER2-, HR+/HER2+, HR-/HER2+, HR-/HER2- [triple negative], missing/unknown); cancer status at time of COVID-
205 19 diagnosis; timing of most recent anti-cancer therapy relative to COVID-19 diagnosis (never or after COVID-19 diagnosis,
206 0-4 weeks, 1-3 months, >3 months); and modality of anti-cancer therapy received within three months of COVID-19
207 diagnosis. Cancer status was defined as remission or no evidence of disease (NED) for >5 years, remission or NED for ≤ 5
208 years, and active disease, with active disease further classified as responding to therapy, stable, or progressing. Anti-cancer
209 modalities were categorized as chemotherapy; cyclin-dependent kinase (CDK) 4/6 inhibitor; anti-HER2 therapy; other
210 targeted therapy (non-CDK 4/6 inhibitor, non-anti-HER2 therapy); endocrine therapy; immunotherapy; and locoregional

211 therapy (surgery and/or radiation). In the survey, drug classes (modalities) along with a few specific drugs (through
212 checkboxes) were captured. Survey respondents were also encouraged to provide additional details in the free text boxes
213 which were reviewed extensively by the Informatics Core at VUMC, and queries were sent to participating sites to clarify
214 ambiguous reports. CDK 4/6 inhibitor, anti-HER2 therapy and other targeted therapy information was extracted from free
215 text in the registry survey while the others were checkboxes. In addition, baseline severity of COVID-19 at presentation,
216 classified as mild (no hospitalization indicated), moderate (hospitalization indicated), and severe (ICU admission indicated)
217 was collected. Other variables included location of patient residence (urban, suburban, rural) and treatment center
218 characteristics (academic medical center, community practice, tertiary care center). The CCC19 data dictionary is available at
219 https://github.com/covidncancer/CCC19_dictionary. The project approved variables used for the analysis are provided in
220 *supplementary appendix*.

221

222 ***Statistical methods***

223 Covariates, outcome definitions, and statistical analysis plan were pre-specified by the authors and the CCC19 Research
224 Coordinating Center prior to analysis (*supplementary appendix*). Standard descriptive statistics were used to summarize
225 prognostic factors, rates of clinical complications, interventions during hospitalization, and rates of outcomes such as 30-day
226 mortality, hospitalization, oxygen requirement, ICU admission, mechanical ventilation, and overall mortality among racial
227 and ethnic groups. The primary analysis was restricted to females with BC.

228

229 Multivariable ordinal logistic regression models for the COVID-19 severity outcome among females with BC included age,
230 race/ethnicity, obesity, ECOG PS, co-morbidities, cancer status, anti-cancer therapy and timing, month/year of COVID-19
231 diagnosis (classified into 4-month intervals), and U.S census region of reporting institution. These covariates were identified
232 *a priori* as the most clinically relevant for COVID-19 severity and were included in a single model, given a sufficient number
233 of events and corresponding degrees of freedom. Because the ordinal outcome was assessed over a given patients' total
234 follow-up period, the model included an offset for (log) follow-up time. The results are presented as adjusted odds ratio
235 (ORs) with 95% CIs. Model stability was assessed by comparing unadjusted and adjusted models and variance inflation
236 factors. Graphical methods were used to verify the proportional odds assumption (*supplementary appendix- figure I*). We
237 used the e value to quantify sensitivity to unmeasured confounding for the observed OR for race/ethnicity.[33], [34] Multiple

238 imputation (20 imputed datasets) was used to impute missing and unknown data for all variables included in the analysis,
239 with some exceptions: unknown ECOG performance score and unknown cancer status were not imputed and treated as a
240 separate category in analyses. Imputation was performed on the largest dataset possible (that is, after removing test cases and
241 other manual exclusions, but before applying specific exclusion criteria). Analyses were completed using R v4.0.4 (R
242 Foundation for Statistical Computing, Vienna, Austria), including the rms and EValue extension packages. Descriptive
243 statistics for males with BC and females with metastatic BC are presented separately but multivariable modeling was not
244 attempted due to small sample sizes.

245

246 **RESULTS**

247 **Baseline characteristics and COVID-19 Outcomes in female patients with BC**

248 Of the total 12,034 reports on all cancers submitted to the CCC19 registry at the time of this analysis, 1,383 females with BC
249 met the eligibility criteria and were included (**Figure I**). The median age for the cohort was 61 years (IQR 51-72 years) and
250 median follow-up was 90 (IQR 30-135) days. BC subtypes by biomarker distribution in CCC19 registry included: 52%
251 HR+/HER2-, 14% HR+/HER2+, 8% HR-/HER2+, 11% triple negative, and 14% unknown or missing. BC subtype
252 distribution based on biomarkers in the CCC19 cohort are similar to SEER data which adds broader applicability of these
253 findings.[35] With regards to BC status, 27% were in remission/NED for over 5 years and 32% were in remission/NED for
254 less than 5 years since the initial BC diagnosis and 32% had active cancer (13% had active and responding, 12% had active
255 and stable and 7% had active and progressing cancer). 57% of patients had received some form of anti-cancer therapy within
256 3 months of COVID-19 diagnosis. The unadjusted total all-cause mortality and hospitalization rate, included in the primary
257 ordinal outcome, for the female cohort was 9% and 37%, respectively. However, the unadjusted rates of COVID-19
258 outcomes varied by their BC status; females with active and progressing cancer had the highest all-cause mortality (38%) and
259 hospitalization rates (72%) compared to the rest of the group (*supplementary appendix - table I*). Other clinical outcomes for
260 the female cohort included 30-day all-cause mortality (6%), mechanical ventilation (5%) and ICU care (8%). Additional
261 details on patients with BC and COVID-19 by specific characteristics of interest are presented below.

262

263

264 ***Characteristics of female patients with BC and COVID-19 by Race/Ethnicity***

265 Of the 1383 female patients, 736 (53%) were NHW, 289 (21%) Black, 235 (17%) Hispanic, 45 (3%) AAPI, and 78 (6%)
266 belonged to Other racial/ethnic group. Baseline characteristics of females stratified by race/ethnicity groups are shown in
267 **Table I**. Hispanic and AAPI patients were younger with median ages of 53 (IQR 46-62) and 54 (IQR 43-73) years
268 respectively, compared to 64 years in NHW (IQR 54-76) and 61 years (IQR 52-69) in Black patients. Prevalence of smokers
269 were higher among NHW (35%), Black (33%) and Other (32%) racial/ethnic groups compared to Hispanic (23%) and AAPI
270 (18%) patients. Rates of obesity was higher in Black (54%) and lower in AAPI (29%) compared to NHW (42%) patients.
271 Cardiovascular comorbidity was less common in Hispanic patients (6%), while diabetes mellitus was more prevalent among
272 Black patients (34%) compared to NHW patients (24% and 17% respectively). Compared to NHW, Hispanic patients had
273 higher rates of active cancer (24% responding, 15% stable, and 9% progressing) and had higher rates of receipt of anti-cancer
274 systemic therapy within 3 months of COVID-19 diagnosis (37% chemotherapy, 25% targeted therapy, 39% endocrine
275 therapy). Similarly, AAPI patients also had higher rates of active cancer (7% responding, 22% stable, and 13% progressing)
276 and received anti-cancer systemic therapy within 3 months of COVID-19 diagnosis (24% chemotherapy, 18% targeted
277 therapy, 33% endocrine therapy) compared to NHW patients with active cancer [9% responding, 12% stable, and 6%
278 progressing] who received anti-cancer systemic therapy [16% chemotherapy, 15% targeted therapy, 38% endocrine therapy]).
279 With regards to baseline severity of COVID-19 at presentation, 39% of Black and 38% of AAPI patients presented with
280 moderate or higher severity of COVID-19 infection compared to 27% in both NHW and Hispanic patients. **Table II**
281 summarizes the clinical outcomes, complications, and interventions, stratified by race/ethnicity.

282

283 ***Characteristics of female patients with Metastatic Breast Cancer (MBC) and COVID-19***

284 Female patients with MBC consisted of 17% of the cohort (N=233), with median age 58 years [IQR 50-68]. Racial/Ethnic
285 groups consisted of 46% NHW, 24% Black, 21% Hispanics, 4% AAPI and 4% Other. Most patients with MBC were never
286 smokers (70%) and non-obese (60%). The predominant tumor biology was HR+/HER2- (42%) followed by
287 HR+/HER2+(23%). The most common sites of metastases were bone (58%), lung (28%), and liver (26%). A high percentage
288 (87%) had received anti-cancer treatment within 3 months prior to COVID-19 diagnosis and 32% had active and progressing
289 cancer. The unadjusted total all-cause mortality and hospitalization rate in females with MBC was 19% and 53%

290 respectively. Further details of baseline characteristics and unadjusted rates of COVID-19 outcomes, complications and
291 interventions are presented in *supplementary appendix – Table IIA and IIB*

292

293 **BC Treatment Characteristics**

294 758 (55%) out of 1383 female patients with BC received some form of systemic treatment within 3 months prior to COVID-
295 19 diagnosis, and specific drug information was available for 679 (90%) (**Table III**). Of these 679 patients, the most common
296 systemic therapy was endocrine therapy alone (n=336, 49.5%). This was followed by chemotherapy in 163 (24%) patients
297 who received it either as single agent (n=55, 8%) or combination chemotherapy (n=60, 9%) or combined with anti-HER2
298 therapy (n=48, 7%). 78 (11.5%) patients received anti-HER2 therapy with or without endocrine therapy, and 63 (9%) patients
299 received CDK4/6 inhibitors with or without endocrine therapy.

300

301 **Prognostic Factors associated with COVID-19 severity**

302 After adjusting for baseline demographic, clinical, and spatiotemporal factors in multivariable analysis model, factors
303 associated with worse outcomes in females with BC included older age (aOR per decade, 1.48 [95% CI, 1.32 – 1.67]); Black
304 (aOR, 1.74 [95% CI, 1.24 - 2.45]), AAPI (aOR, 3.40 [95% CI, 1.70 - 6.79]), and Other (aOR, 2.97 [95% CI, 1.71 - 5.17])
305 racial/ethnic group; cardiovascular (aOR, 2.26 [95% CI, 1.63 – 3.15]) and pulmonary (aOR, 1.65 [95% CI, 1.20 – 2.29])
306 comorbidities; diabetes mellitus (aOR, 2.25 [95% CI, 1.66 – 3.04]); worse ECOG PS (ECOG PS 1: aOR, 1.74 [95% CI, 1.22
307 – 2.48]; ECOG PS \geq 2: aOR, 7.78 [95% CI, 4.83 – 12.5]); and active and progressing cancer status (aOR, 12.5 [95% CI, 6.89
308 – 22.6]). Association between Hispanic ethnicity, obesity, preexisting renal disease, anti-cancer treatment modalities
309 including all forms of systemic therapy and loco-regional therapy, month/year and geographic region of COVID-19 diagnosis
310 and COVID-19 severity did not reach statistical significance (**Table IV**). The e value for the COVID-19 severity OR and CI
311 for each racial group are shown in *supplementary appendix - Table III*. This value demonstrates the impact of unknown
312 *_residual_* confounding above that adjusted for by including adjustment variables in the multivariable model. For example,
313 an unmeasured confounder would need to be associated with both race and mortality with a odds ratio of at least 1.97 to fully
314 attenuate the observed association for Black females and the odds ratio would need to be at least 1.47 for the null-
315 hypothesized value (1.0) to be included in the CI. Similarly, E value estimates are noted for AAPI and Other groups. The

316 unmeasured confounding for other races based on the e value is larger than most documented associations in the CCC19
317 cohort. [3]

318

319 **Male patients with BC and COVID-19**

320 Male patients with BC were evaluated separately as part of exploratory analysis. The median age for male BC cohort (N=25)
321 was 67 years [IQR 60-75]. Racial/ethnic composition consisted of NHW (52%) followed by Black (32%) males. Most males
322 with BC were non-smokers (72%) and diabetes mellitus was the predominant comorbidity (44%). The hospitalization rate
323 was 60% and all-cause mortality was 20%. Additional clinical characteristics, complications, interventions, and unadjusted
324 outcomes among males with BC in the CCC19 registry are provided in *supplementary appendix – table IV*.

325

326 **DISCUSSION**

327 In this large, multi-institutional and racially diverse cohort of females with BC and COVID-19 from CCC19 registry, we
328 assessed the clinical impact of COVID-19. The all-cause mortality from COVID-19 was 9% and hospitalization rate was
329 37%, which is numerically lower than in the entire CCC19 cohort at 14% and 58%, and other previously reported studies of
330 COVID-19 in patients with cancer.[3]–[8], [36] These differences in outcomes could indicate differences in the
331 immunocompromised status of patients due to intensity of therapy regimens, complex comorbidities, or concomitant
332 medications, which may affect outcomes. Females with BC, however, form a heterogenous group, and the rates of outcomes
333 varied widely with their disease status; patients with active and progressing cancer had the highest total all-cause mortality
334 (38%) and hospitalization rates (72%).

335

336 We observed older age, pre-existing cardiovascular and pulmonary comorbidities, diabetes mellitus, worse ECOG PS, and
337 active and progressing cancer status were associated with adverse COVID-19 outcomes in females with BC. Prior studies
338 have reported similar factors to be associated with adverse COVID-19 outcomes in patients with all cancer types. The
339 majority of these studies have reported older age to be an important prognostic factor for adverse outcomes from COVID-19,
340 including mortality, which is consistent with data presented here.[3], [9], [10], [36], [37] Non-cancer comorbidities,
341 contributing to poor COVID-19 outcomes, as noted in our study, have also been a consistent finding in patients with and
342 without a cancer diagnosis.[3], [9], [10], [37], [38] Similarly, poor ECOG PS in cancer patients has been noted to be an

343 important factor associated with worse COVID-19 severity, including our study.[3], [8], [10] While obesity was reported in
344 some cancer studies to have a negative impact on COVID-19 [3], [37], our study did not identify this association. In this
345 cohort of females with BC, all forms of anti-cancer therapy were thoroughly evaluated and none of the systemic therapies
346 including chemotherapy; endocrine therapy; and targeted therapy (anti-HER2, CDK4/6 inhibitors, other non-HER2 or non-
347 CDK4/6 inhibitors); or loco-regional therapy (surgery and radiation) received within 3 months of COVID-19 diagnosis was
348 significantly associated with adverse COVID-19 outcomes. Our finding suggests that systemic therapy for females with BC
349 may not add excess COVID-19 risk. Multiple large cohort studies and meta-analysis of patients with cancer diagnosed with
350 COVID-19 similarly did not identify active anti-cancer therapy, specifically chemotherapy, as a factor associated with
351 adverse COVID-19 outcomes, which is consistent with our results.[4], [5], [8], [36], [39], [40] However, in contrast, some
352 studies of patients with other cancers have shown a negative impact of chemotherapy[3], [9], [10], [37] and immunotherapy
353 use [37]. These findings have important clinical implications while counselling and providing patient care during the
354 pandemic.

355
356 We also report important findings related to the impact of racial/ethnic inequities in females with BC and COVID-19, which
357 adds to the growing body of literature on COVID-19 related racial/ethnic disparities. In our study, Black females with BC
358 had significantly worse COVID-19 outcomes compared to NHW females. Multiple studies have similarly reported Black
359 patients in US with and without cancer diagnosis having significantly worse COVID-19 outcomes [3], [6], [11] however, our
360 study is the first to show such racial/ethnic disparities in COVID-19 outcomes in females with BC. There was no statistically
361 significant association of worse outcomes for Hispanic females compared to NHW females. This is different in comparison to
362 our overall CCC19 cohort[3], and may be explained by younger age and lower rates of comorbid conditions in Hispanic
363 females compared to NHW females. We also found females belonging to AAPI, and Other racial/ethnic group to have worse
364 COVID-19 outcomes. Notably, females belonging to Black, AAPI and Other racial/ethnic groups presented with higher rates
365 of moderate or severe symptoms of COVID-19 at baseline, which likely contributed to their worse outcomes. This in turn is
366 possibly related to barriers to health care access, and other socio-cultural reasons for delay in seeking early medical care.
367 Future studies including social determinants of health, access to health care, and lifestyle behaviors, among others, are
368 warranted to identify barriers contributing to worse clinical presentation in racial/ethnic minority groups, and eventually
369 impacting future health policies.

370

371 In summary, this is one of the largest cohort studies to evaluate the clinical impact of COVID-19 on females with BC.
372 Strengths of our study include standardized data collection on the most common cancer in females in the US and large
373 sample size to evaluate the effect of major clinical and demographic factors. The study had representative population by race
374 and ethnicity from geographically diverse areas and variable time/period of COVID-19 diagnosis. In addition, our study has
375 detailed manually collected information on both cancer status and treatment modalities which contrasts with other studies that
376 have utilized either of these variables as surrogate. Limitations of this study include the retrospective nature of data and
377 inherent potential for confounding because of its observational nature. It's possible that ascertainment bias could have led to
378 some of the high values observed in specific groups such as females with MBC and those with active and progressing cancer.
379 Additional information on drivers for inequity such as socio-economic status, occupation, income, residence, education, and
380 insurance status may have provided added insights on the root causes for disparities; however, unavailability of these factors
381 does not nullify our current findings of existing racial disparities in COVID-19 outcomes in females with BC. Vaccination
382 status was not part of this study as vaccines were not available during the predominant time frame for this cohort. Data
383 presented here including the risk of hospitalization and death applies to the specific COVID-19 variants prevalent during the
384 study period. Despite these limitations, the study reports important sociodemographic and clinical factors that aid in
385 identifying females with BC who are at increased risk for severe COVID-19 outcomes.

386

387 Our study addresses an important knowledge gap in patients with BC diagnosed with COVID-19 using the CCC19 registry.
388 In addition to clinical and demographic factors associated with adverse COVID-19 outcomes, racial/ethnic disparities
389 reported here significantly contribute to the growing literature. At this stage, it is irrefutable that one of the principal far-
390 reaching messages the pandemic has conveyed is that any such major stressors on the health care system increases risk of
391 detrimental outcomes to the most vulnerable patient population, including the underrepresented and the underserved. These
392 are important considerations for future resource allocation strategies and policy interventions. We also report an important
393 finding that cancers that are active and progressing are associated with severe COVID-19 outcomes. During the ongoing
394 pandemic, this has significant implications for shared decision-making between patients and physicians.

395

396

397 **REFERENCES**

- 398 [1] “WHO Coronavirus (COVID-19) Dashboard.” <https://covid19.who.int> (accessed Dec. 14, 2021).
- 399 [2] CDC, “COVID Data Tracker,” *Centers for Disease Control and Prevention*, Mar. 28, 2020.
- 400 <https://covid.cdc.gov/covid-data-tracker> (accessed Dec. 14, 2021).
- 401 [3] P. Grivas *et al.*, “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients
- 402 with cancer: a report from the COVID-19 and Cancer Consortium,” *Ann Oncol*, vol. 32, no. 6, pp. 787–800, Jun. 2021,
- 403 doi: 10.1016/j.annonc.2021.02.024.
- 404 [4] M. C. Garassino *et al.*, “COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an
- 405 international, registry-based, cohort study,” *Lancet Oncol*, vol. 21, no. 7, pp. 914–922, Jul. 2020, doi: 10.1016/S1470-
- 406 2045(20)30314-4.
- 407 [5] L. Y. Lee *et al.*, “COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a
- 408 prospective cohort study,” *Lancet*, vol. 395, no. 10241, pp. 1919–1926, Jun. 2020, doi: 10.1016/S0140-
- 409 6736(20)31173-9.
- 410 [6] Q. Wang, N. A. Berger, and R. Xu, “Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With
- 411 Cancer and COVID-19 Infection,” *JAMA Oncol*, vol. 7, no. 2, pp. 220–227, Feb. 2021, doi:
- 412 10.1001/jamaoncol.2020.6178.
- 413 [7] E. de Azambuja *et al.*, “Impact of solid cancer on in-hospital mortality overall and among different subgroups of
- 414 patients with COVID-19: a nationwide, population-based analysis,” *ESMO Open*, vol. 5, no. 5, p. e000947, Sep. 2020,
- 415 doi: 10.1136/esmoopen-2020-000947.
- 416 [8] L. Albiges *et al.*, “Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the
- 417 Gustave Roussy cohort,” *Nat Cancer*, vol. 1, no. 10, pp. 965–975, Oct. 2020, doi: 10.1038/s43018-020-00120-5.
- 418 [9] N. Sharafeldin *et al.*, “Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort
- 419 Collaborative (N3C),” *J Clin Oncol*, vol. 39, no. 20, pp. 2232–2246, Jul. 2021, doi: 10.1200/JCO.21.01074.
- 420 [10] A. Lièvre *et al.*, “Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer
- 421 patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-
- 422 19),” *Eur J Cancer*, vol. 141, pp. 62–81, Dec. 2020, doi: 10.1016/j.ejca.2020.09.035.
- 423 [11] CDC, “Community, Work, and School,” *Centers for Disease Control and Prevention*, Feb. 11, 2020,
- 424 <https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/racial-ethnic-disparities/index.html> (accessed
- 425 Oct. 04, 2021).
- 426 [12] G. A. Millett *et al.*, “Assessing differential impacts of COVID-19 on black communities,” *Ann Epidemiol*, vol. 47, pp.
- 427 37–44, Jul. 2020, doi: 10.1016/j.annepidem.2020.05.003.
- 428 [13] L. S. Muñoz-Price *et al.*, “Racial Disparities in Incidence and Outcomes Among Patients With COVID-19,” *JAMA*
- 429 *Network Open*, vol. 3, no. 9, p. e2021892, Sep. 2020, doi: 10.1001/jamanetworkopen.2020.21892.
- 430 [14] C. P. Gross, U. R. Essien, S. Pasha, J. R. Gross, S. Wang, and M. Nunez-Smith, “Racial and Ethnic Disparities in
- 431 Population-Level Covid-19 Mortality,” *J Gen Intern Med*, vol. 35, no. 10, pp. 3097–3099, Oct. 2020, doi:
- 432 10.1007/s11606-020-06081-w.
- 433 [15] E. G. Price-Haywood, J. Burton, D. Fort, and L. Seoane, “Hospitalization and Mortality among Black Patients and
- 434 White Patients with Covid-19,” *N Engl J Med*, vol. 382, no. 26, pp. 2534–2543, Jun. 2020, doi:
- 435 10.1056/NEJMsa2011686.
- 436 [16] K. M. J. Azar *et al.*, “Disparities In Outcomes Among COVID-19 Patients In A Large Health Care System In
- 437 California,” *Health Aff (Millwood)*, vol. 39, no. 7, pp. 1253–1262, Jul. 2020, doi: 10.1377/hlthaff.2020.00598.
- 438 [17] K. Mackey *et al.*, “Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths : A
- 439 Systematic Review,” *Ann Intern Med*, vol. 174, no. 3, pp. 362–373, Mar. 2021, doi: 10.7326/M20-6306.
- 440 [18] S. Garg *et al.*, “Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed
- 441 Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020,” *MMWR Morb Mortal Wkly Rep*, vol. 69, no.
- 442 15, pp. 458–464, Apr. 2020, doi: 10.15585/mmwr.mm6915e3.
- 443 [19] U. V. Mahajan and M. Larkins-Pettigrew, “Racial demographics and COVID-19 confirmed cases and deaths: a
- 444 correlational analysis of 2886 US counties,” *J Public Health (Oxf)*, vol. 42, no. 3, pp. 445–447, Aug. 2020, doi:
- 445 10.1093/pubmed/fdaa070.
- 446 [20] S. J. Kim and W. Bostwick, “Social Vulnerability and Racial Inequality in COVID-19 Deaths in Chicago,” *Health*
- 447 *Educ Behav*, vol. 47, no. 4, pp. 509–513, Aug. 2020, doi: 10.1177/1090198120929677.
- 448 [21] J. Fu *et al.*, “Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer,” *JAMA*
- 449 *Network Open*, vol. 5, no. 3, p. e224304, Mar. 2022, doi: 10.1001/jamanetworkopen.2022.4304.

- 450 [22] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, "Cancer Statistics, 2021," *CA Cancer J Clin*, vol. 71, no. 1, pp.
451 7–33, Jan. 2021, doi: 10.3322/caac.21654.
- 452 [23] H. Sung *et al.*, "Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36
453 Cancers in 185 Countries," *CA: A Cancer Journal for Clinicians*, vol. 71, no. 3, pp. 209–249, 2021, doi:
454 10.3322/caac.21660.
- 455 [24] "Cancer of the Breast (Female) - Cancer Stat Facts," *SEER*. <https://seer.cancer.gov/statfacts/html/breast.html> (accessed
456 Oct. 06, 2021).
- 457 [25] R. T. Chlebowski *et al.*, "Ethnicity and breast cancer: factors influencing differences in incidence and outcome," *J Natl*
458 *Cancer Inst*, vol. 97, no. 6, pp. 439–448, Mar. 2005, doi: 10.1093/jnci/dji064.
- 459 [26] J. Bigby and M. D. Holmes, "Disparities across the breast cancer continuum," *Cancer Causes Control*, vol. 16, no. 1,
460 pp. 35–44, Feb. 2005, doi: 10.1007/s10552-004-1263-1.
- 461 [27] C. G. Yedjou *et al.*, "Health and Racial Disparity in Breast Cancer," *Adv Exp Med Biol*, vol. 1152, pp. 31–49, 2019,
462 doi: 10.1007/978-3-030-20301-6_3.
- 463 [28] P. Vuagnat *et al.*, "COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area," *Breast*
464 *Cancer Res*, vol. 22, no. 1, p. 55, May 2020, doi: 10.1186/s13058-020-01293-8.
- 465 [29] K. Kalinsky *et al.*, "Characteristics and outcomes of patients with breast cancer diagnosed with SARS-Cov-2 infection
466 at an academic center in New York City," *Breast Cancer Res Treat*, pp. 1–4, May 2020, doi: 10.1007/s10549-020-
467 05667-6.
- 468 [30] N. M. Kuderer *et al.*, "Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study," *Lancet*, vol.
469 395, no. 10241, pp. 1907–1918, Jun. 2020, doi: 10.1016/S0140-6736(20)31187-9.
- 470 [31] COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org and COVID-19 and Cancer
471 Consortium, "A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19
472 Governance, Protocol, and Quality Assurance," *Cancer Cell*, vol. 38, no. 6, pp. 761–766, Dec. 2020, doi:
473 10.1016/j.ccell.2020.10.022.
- 474 [32] "PHIN Vocabulary | CDC," Sep. 29, 2021. <https://www.cdc.gov/phin/resources/vocabulary/index.html> (accessed Oct.
475 05, 2021).
- 476 [33] T. J. VanderWeele and P. Ding, "Sensitivity Analysis in Observational Research: Introducing the E-Value," *Ann Intern*
477 *Med*, vol. 167, no. 4, pp. 268–274, Aug. 2017, doi: 10.7326/M16-2607.
- 478 [34] S. Haneuse, T. J. VanderWeele, and D. Arterburn, "Using the E-Value to Assess the Potential Effect of Unmeasured
479 Confounding in Observational Studies," *JAMA*, vol. 321, no. 6, pp. 602–603, Feb. 2019, doi:
480 10.1001/jama.2018.21554.
- 481 [35] "Female Breast Cancer Subtypes - Cancer Stat Facts," *SEER*. [https://seer.cancer.gov/statfacts/html/breast-](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)
482 *subtypes.html* (accessed Feb. 26, 2022).
- 483 [36] H. Zhang *et al.*, "Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review
484 and Meta-Analysis," *J Natl Cancer Inst*, vol. 113, no. 4, pp. 371–380, Apr. 2021, doi: 10.1093/jnci/djaa168.
- 485 [37] M. Chavez-MacGregor, X. Lei, H. Zhao, P. Scheet, and S. H. Giordano, "Evaluation of COVID-19 Mortality and
486 Adverse Outcomes in US Patients With or Without Cancer," *JAMA Oncology*, Oct. 2021, doi:
487 10.1001/jamaoncol.2021.5148.
- 488 [38] CDC, "Coronavirus Disease 2019 (COVID-19)," *Centers for Disease Control and Prevention*, Feb. 11, 2020.
489 <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/underlying-evidence-table.html> (accessed Nov. 10,
490 2021).
- 491 [39] H. Liu *et al.*, "The effect of anticancer treatment on cancer patients with COVID-19: A systematic review and meta-
492 analysis," *Cancer Med*, vol. 10, no. 3, pp. 1043–1056, Feb. 2021, doi: 10.1002/cam4.3692.
- 493 [40] J. Jee *et al.*, "Chemotherapy and COVID-19 Outcomes in Patients With Cancer," *J Clin Oncol*, vol. 38, no. 30, pp.
494 3538–3546, Oct. 2020, doi: 10.1200/JCO.20.01307.
- 495

497

498

499 **DATA AVAILABILITY:** <https://datadryad.org/stash/dataset/doi:10.5061/dryad.1g1jwsv10>

500 **ETHICS APPROVAL:**

501 This study was exempt from institutional review board (IRB) review (VUMC IRB#200467) and was approved by IRBs at
502 participating sites per institutional policy.

503

504 **ACKNOWLEDGEMENTS:** We thank all members of the CCC19 steering committee: Toni K. Choueiri, Narjust Duma,

505 Dimitrios Farmakiotis, Petros Grivas, Gilberto de Lima Lopes Jr., Corrie A. Painter, Solange Peters, Brian I. Rini, Dimpy P.

506 Shah, Michael A. Thompson, and Jeremy L. Warner, for their invaluable guidance of the COVID-19 and Cancer Consortium.

507

Table I: Baseline Characteristics by Race/Ethnicity						
	NHW (n = 736, 53%)	Black (n = 289, 21%)	Hispanic (n = 235, 17%)	AAPI (n = 45, 3%)	Others (n=78, 6%)	All (n = 1383, 100%)
Median Age, years^a [IQR]	64 (54-76)	61 (52-69)	53 (46-62)	54 (43-73)	62 (53-71)	61 (51-72)
Median follow-up, days [IQR]	90 (30-135)	90 (30-180)	90 (30-135)	42 (21-90)	70 (30-180)	90 (30-135)
Smoking status						
Never	460 (62%)	186 (64%)	180 (77%)	35 (78%)	50 (64%)	911 (66%)
Current or Former	261 (35%)	95 (33%)	53 (23%)	8 (18%)	25 (32%)	442 (32%)
Missing/unknown	15 (2%)	8 (3%)	2 (1%)	2 (4%)	3(4%)	30 (2%)
Obesity						
No	421 (57%)	133 (46%)	116 (49%)	32 (71%)	45 (58%)	747 (54%)
Yes	308 (42%)	156 (54%)	116 (49%)	13 (29%)	33 (42%)	626 (45%)
Missing/unknown	7 (1%)	0 (0%)	3 (1%)	0 (0%)	0 (0%)	10 (1%)
Comorbidities^b						
Cardiovascular	179 (24%)	60 (21%)	14 (6%)	7 (16%)	11 (14%)	271 (20%)
Pulmonary	125 (17%)	65 (22%)	33 (14%)	<5 (<11%)	7 (9%)	234 (17%)
Renal Disease	66 (9%)	31 (11%)	13 (6%)	<5 (<11%)	<5 (<6%)	115 (8%)
Diabetes mellitus	127 (17%)	98 (34%)	51 (22%)	10 (22%)	20 (26%)	306 (22%)
Missing/unknown	9 (1%)	1 (<1%)	5 (2%)	0 (0%)	0 (0%)	15 (1%)
ECOG performance status						
0	314 (43%)	130 (45%)	123 (52%)	18 (40%)	32 (41%)	617 (45%)
1	135 (18%)	72 (25%)	48 (20%)	10 (22%)	16 (21%)	281 (20%)
2+	69 (9%)	33 (11%)	15 (6%)	5 (11%)	5 (6%)	127 (9%)
Unknown	218 (30%)	53 (18%)	49 (21%)	12 (27%)	25 (32%)	357 (26%)
Missing	0 (0%)	1 (<1%)	0 (0%)	0 (0%)	0 (0%)	1 (<1%)
Region						
Northeast	247 (34%)	101 (35%)	106 (45%)	12 (27%)	26 (33%)	492 (36%)
Midwest	239 (32%)	110 (38%)	23 (10%)	8 (18%)	12 (15%)	392 (28%)
South	116 (16%)	58 (20%)	27 (11%)	X*	14 (18%)	218 (16%)
West	128 (17%)	16 (6%)	77 (33%)	22 (49%)	24 (31%)	267 (19%)
Undesignated	6 (1%)	4 (1%)	2 (1%)	3 (7%)*	2 (3%)	14 (1%)
Month/Year of COVID-19 diagnosis						
Jan-Apr 2020	140 (19%)	74 (26%)	41 (17%)	8 (18%)	20 (26%)	283 (20%)
May-Aug 2020	279 (38%)	141 (49%)	101 (43%)	24 (53%)	30 (38%)	575 (42%)
Sept-Dec 2020	197 (27%)	42 (15%)	50 (21%)	5 (11%)	16 (21%)	310 (22%)
Jan-Jun 2021	118 (16%)	32 (11%)	41 (17%)	7 (16%)	12 (15%)	210 (15%)
Missing/unknown	2 (<1%)	0 (0%)	2 (1%)	1 (2%)	0 (0%)	5 (<1%)
Area of patient residence						
Urban	193 (26%)	136 (47%)	124 (53%)	13 (29%)	30 (38%)	496 (36%)
Suburban	315 (43%)	77 (27%)	65 (28%)	17 (38%)	31 (40%)	505 (37%)
Rural	81 (11%)	7 (2%)	9 (4%)	X*	0 (0%)	98 (7%)

Missing/unknown	147 (20%)	69 (24%)	37 (16%)	15 (33%)*	17 (22%)	284 (21%)
Treatment center characteristics						
Academic Medical Center	123 (17%)	102 (35%)	43 (18%)	7 (16%)	11 (14%)	286 (21%)
Community Practice	238 (32%)	51 (18%)	44 (19%)	X*	23 (29%)	359 (26%)
Tertiary Care Center	375 (51%)	136 (47%)	147 (63%)	35 (78%)	44 (56%)	737 (53%)
Missing/unknown	0 (0%)	0 (0%)	1 (<1%)	3 (7%)*	0 (0%)	1 (<1%)
Receptor status						
HR+/HER2-	419 (57%)	135 (47%)	102 (43%)	22 (49%)	43 (55%)	721 (52%)
HR+/HER2+	102 (14%)	35 (12%)	43 (18%)	7 (16%)	9 (12%)	196 (14%)
HR-/HER2+	46 (6%)	28 (10%)	32 (14%)	X*	X*	111 (8%)
Triple Negative	57 (8%)	54 (19%)	35 (15%)	5 (11%)	7 (9%)	158 (11%)
Missing/unknown	112 (15%)	37 (13%)	23 (10%)	11 (24%)*	19 (24%)*	197 (14%)
Cancer status						
Remission/NED, >5 yrs	247 (34%)	76 (26%)	23 (10%)	9 (20%)	20 (26%)	375 (27%)
Remission/NED, <5 yrs	234 (32%)	100 (35%)	77 (33%)	11 (24%)	26 (33%)	448 (32%)
Active and responding	68 (9%)	35 (12%)	56 (24%)	X*	11 (14%)	173 (13%)
Active and stable	91 (12%)	28 (10%)	35 (15%)	10 (22%)	5 (6%)	169 (12%)
Active and progressing	41 (6%)	27 (9%)	20 (9%)	6 (13%)	X*	97 (7%)
Unknown	48 (7%)	19 (7%)	22 (9%)	6 (13%)*	15 (19%)*	104 (8%)
Missing	7 (1%)	4 (1%)	2 (1%)	3 (7%)	1 (1%)	17 (1%)
Timing of anti-cancer therapy						
Never/After COVID-19	24 (3%)	10 (3%)	7 (3%)	X*	7 (9%)	50 (4%)
0-4 weeks	364 (49%)	135 (47%)	158 (67%)	25 (56%)	39 (50%)	721 (52%)
1-3 months	26 (4%)	20 (7%)	19 (8%)	0 (0%)	X*	69 (5%)
>3 months	303 (41%)	118 (41%)	45 (19%)	18 (40%)	24 (31%)	508 (37%)
Missing/unknown	19 (3%)	6 (2%)	6 (3%)	2 (4%)*	8 (10%)*	35 (3%)
Modality of active anti-cancer therapy^{b,c}						
None	333 (45%)	127 (44%)	53 (23%)	20 (44%)	30 (38%)	563 (41%)
Chemotherapy	117 (16%)	68 (24%)	88 (37%)	11 (24%)	14 (18%)	298 (22%)
Targeted Therapy	112 (15%)	38 (13%)	59 (25%)	8 (18%)	11 (14%)	228 (16%)
<i>Anti-HER2 therapy</i>	60 (8%)	17 (6%)	36 (15%)	<5 (<11%)	<5 (<6%)	123 (9%)
<i>CDK4/6 inhibitor</i>	33 (4%)	12 (4%)	14 (6%)	<5 (<11%)	<5 (<6%)	65 (5%)
<i>Other^d</i>	14 (2%)	5 (2%)	<5 (<2%)	<5 (<11%)	0 (0%)	24 (2%)
Endocrine Therapy	283 (38%)	86 (30%)	91 (39%)	15 (33%)	26 (33%)	501 (36%)
Immunotherapy	12 (2%)	8 (3%)	<5 (<2%)	<5 (<11%)	<5 (<6%)	28 (2%)
Local (Surgery/Radiation)	80 (11%)	37 (13%)	41 (17%)	<5 (<11%)	9 (12%)	172 (12%)
Other	13 (2%)	3 (1%)	2 (1%)	0 (0%)	0 (0%)	18 (1%)
Missing/unknown	12 (2%)	7 (2%)	5 (2%)	0 (0%)	5 (6%)	29 (2%)
Severity of COVID-19						
Mild	535 (73%)	177 (61%)	173 (74%)	28 (62%)	50 (64%)	963 (70%)
Moderate	174 (24%)	97 (34%)	56 (24%)	14 (31%)	21 (27%)	362 (26%)
Severe	25 (3%)	15 (5%)	6 (3%)	X*	7 (9%)	56 (4%)
Missing/unknown	2 (<1%)	0 (0%)	0 (0%)	3 (7%)*	0 (0%)	2 (<1%)

*Cells combined to mask N<5 according to CCC19 low count policy
^a Age was truncated at 90
^b Percentages could sum to >100% because categories are not mutually exclusive
^c Within 3 months of COVID-19 diagnosis.
^d Therapies other than Anti-Her2 therapy or CDK4/6 inhibitor
Variable categories with one to five cases are masked by replacing with N < 5 according to CCC19 policy

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

Table II: Outcomes, Clinical Complications, and COVID-19 Interventions

	NHW n ^a (%)	Black n ^a (%)	Hispanic n ^a (%)	AAPI n ^a (%)	Other n ^a (%)	All n ^a (%)
Outcomes						
Total all-cause mortality ^b	60 (8)	38 (13)	12 (5)	<5 (<11)	9 (12)	123 (9)
30-day all-cause mortality ^c	40 (5)	29 (10)	8 (3)	<5 (<11)	8 (10)	89 (6)
Received mechanical ventilation ^b	24 (3)	26 (9)	11 (5)	<5 (<11)	<5 (<6)	69 (5)
Admitted to an intensive care unit ^b	45 (6)	31 (11)	18 (8)	7 (16)	10 (13)	111 (8)
Admitted to the hospital ^b	245 (33)	137 (47)	77 (33)	20 (44)	33 (42)	512 (37)
Clinical complications						
Any cardiovascular complication ^d	82 (11)	50 (17)	30 (13)	6 (13)	18 (23)	186 (14)
Any pulmonary complication ^e	170 (23)	88 (31)	43 (18)	12 (27)	23 (30)	336 (24)
Any gastrointestinal complication ^f	12 (2)	7 (2)	<5 (<2)	<5 (<11)	<5 (<7)	26 (2)
Acute kidney injury	41 (6)	46 (16)	11 (5)	5 (11)	10 (13)	113 (8)
Multisystem organ failure	10 (1)	12 (4)	<5 (<2)	<5 (<11)	<5 (<7)	29 (2)
Superimposed infection	62 (9)	42 (15)	14 (6)	7 (16)	<5 (<7)	129 (10)
Sepsis	43 (6)	24 (8)	15 (6)	7 (16)	12 (16)	101 (7)
Any bleeding	15 (2)	7 (2)	<5 (<2)	<5 (<11)	<5 (<7)	29 (2)
Interventions						
Remdesivir	68 (10)	20 (7)	15 (7)	8 (18)	5 (7)	116 (9)
Hydroxychloroquine	60 (9)	41 (15)	14 (6)	<5 (<11)	11 (15)	129 (10)
Systemic Corticosteroids	107 (15)	50 (18)	31 (14)	8 (18)	13 (18)	209 (16)
Other	112 (16)	53 (19)	36 (16)	11 (25)	12 (17)	224 (17)
Supplemental oxygen	173 (24)	87 (31)	43 (19)	14 (31)	24 (31)	341 (25)

Variable categories with one to five cases are masked by replacing with N < 5 according to CCC19 policy

^a N based on number of patients with non-missing data.

^b Included in primary outcome

^c Secondary outcome

^d Cardiovascular complication includes hypotension, myocardial infarction, other cardiac ischemia, atrial fibrillation, ventricular fibrillation, other cardiac arrhythmia, cardiomyopathy, congestive heart failure, pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, thrombosis NOS complication.

^e Pulmonary complication includes respiratory failure, pneumonitis, pneumonia, acute respiratory distress syndrome (ARDS), PE, pleural effusion, empyema.

^f Gastrointestinal complication includes acute hepatic injury, ascites, bowel obstruction, bowel perforation, ileus, peritonitis

526

527

528

529

Table III: Systemic Treatments Received within 3 months prior to COVID-19 Diagnosis

	N (%)
Total	679 (100%)
Endocrine therapy alone	336 (49.5)
CDK4/6 inhibitor +/- Endocrine therapy	63 (9)
Other targeted therapy +/- Endocrine therapy	10 (1.5)
Anti-HER2 therapy +/- Endocrine therapy	78 (11.5)
Anti-HER2 therapy + Chemotherapy	48 (7)
Single agent chemotherapy +/- Endocrine therapy	55 (8)
Combination chemotherapy +/- Endocrine therapy	60 (9)
Immunotherapy +/- Chemotherapy	19 (3)
Other combination therapies	10 (1.5)

530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560

Table IV: Adjusted Associations of Baseline Characteristics with COVID-19 Severity Outcome.

	COVID-19 severity OR (95% CI)
Age (per decade)	1.48 (1.32- 1.67)
Race (Ref: Non-Hispanic White)^a	
Non-Hispanic Black	1.74 (1.24- 2.45)
Hispanic	1.38 (0.93- 2.05)
Non-Hispanic AAPI	3.40 (1.70- 6.79)
Other	2.97 (1.71- 5.17)
Obesity (Ref: No)	1.20 (0.92- 1.57)
Cardiovascular Comorbidity (Ref: No)	2.26 (1.63- 3.15)
Pulmonary Comorbidity (Ref: No)	1.65 (1.20- 2.29)
Renal Disease (Ref: No)	1.34 (0.86- 2.07)
Diabetes Mellitus (Ref: No)	2.25 (1.66- 3.04)
ECOG Performance Status (Ref: 0)	
1	1.74 (1.22- 2.48)
2+	7.78 (4.83-12.5)
Unknown	2.26 (1.61- 3.19)
Cancer Status (Ref: Remission/NED, >5 years)	
Remission or NED, <5 years	0.91 (0.63- 1.33)
Active and responding	1.07 (0.63- 1.83)
Active and stable	1.37 (0.82- 2.28)
Active and progressing	12.5 (6.89-22.6)
Unknown	1.79 (0.96- 3.34)
Chemotherapy (Ref: No)	1.37 (0.91- 2.06)
Anti-HER2 Therapy (Ref: No)	1.13 (0.67- 1.92)
CDK 4/6 inhibitor (Ref: No)	1.21 (0.60- 2.42)
Other Targeted Therapies^b (Ref: No)	1.78 (0.69- 4.59)
Endocrine Therapy (Ref: No)	1.00 (0.73- 1.37)
Locoregional Therapy (Ref: No)	1.36 (0.88- 2.10)
Never received cancer treatment (Ref: >3 month)	0.65 (0.28- 1.49)
Month/Year of COVID-19 Diagnosis (Ref: Jan-Apr 2020)	
May-Aug 2020	0.57 (0.41- 0.81)
Sept-Dec 2020	0.45 (0.30- 0.68)
Jan-Jun 2021	0.57 (0.36- 0.89)
Region (Ref: Northeast)	

Midwest	0.76 (0.54- 1.05)
South	0.76 (0.51- 1.13)
West	0.43 (0.29- 0.65)


^a Odds ratios greater than 1 indicate higher odds of composite outcome. The P value for evaluating the null hypothesis of equality in odds ratios across race (4 degrees of freedom) was <0.001.

^b Therapies other than CDK4/6 inhibitor or Anti- HER2 therapy

All variance inflation factors are <1.8 for the model

561
562
563
564
565
566
567
568
569
570
571
572

Figure I: Consort Flow Diagram



^a Some Non-melanoma skin cancer, in situ cancers, premalignant conditions are excluded in this step.

^b Manual exclusions = Duplicate records; In situ solid malignancy; Precursor hematologic condition; Benign hematologic condition; False positive SARS-CoV-2 test; Non-melanoma skin cancer; Non-invasive cancer; Low-quality score; Non-CCC29 site.

^c Breast cancer defined as active or previous history of single primary breast cancer. Multiple primary cancers or bilateral breast cancer with exception of DCIS in the contralateral breast cancer were excluded.

^d Data quality problems were classified as minor (1 point), moderate (3 points), and major (5 points) and reports with quality scores > 4 using previously defined metrics were excluded

573

574 **Supplementary Appendix**

575 TABLE OF CONTENTS

576

577	APPENDIX A: CCC-19 Quality Scores	Page: 6
578		
579	APPENDIX B: Breast Cancer Disparities Statistical Analysis Plan:	Pages: 7-13
580		
581	APPENDIX C: CCC19 Approved Project Variables	Pages:14-20
582		
583	APPENDIX D: Supplementary Figure I - Proportional Odds Assumption	Page:21
584		
585	APPENDIX E: Suppl Table I – Unadjusted rates of outcomes after	
586	COVID-19 diagnosis by cancer status	Page:22
587		
588	APPENDIX F: Suppl Table IIA and IIB: Baseline Characteristics of Females	
589	with MBC and unadjusted rates of outcomes after COVID-19 diagnosis	Pages: 23-26
590		
591	APPENDIX G: Suppl Table III: Sensitivity Analysis by Race/Ethnicity	Page: 27
592		
593	APPENDIX H: Suppl Table IVA & IVB - Male Breast Cancer	Pages: 28-30
594		
595	APPENDIX I: List of Participants by Institution	Pages: 31-34

596

597

598

599

600

601

602

603

604

605

606

607 **APPENDIX A: CCC-19 Quality Scores**

608

609 The CCC-19 uses a quality scoring system to determine the suitability of records for inclusion in analyses. A score greater
610 than 5 was considered insufficient for inclusion in the analysis presented. Scores are tabulated as follows:

611

Minor problems (+1 points per problem)

ADT missing/unknown (prostate cancers only)
Biomarkers missing/unknown (breast cancers only)
ICU admission missing/unknown
Hospitalization missing/unknown
Mechanical ventilation missing/unknown
O2 ever needed missing/unknown
Days to death missing/unknown
Cancer status unknown
ECOG PS unknown
Missing cancer drug names for patients on systemic anti-cancer treatment
Missing or unknown categorical lab values if labs were drawn

Moderate problems (+3 points per problem)

Cancer status missing
ECOG PS missing
Death status missing/unknown
Baseline COVID-19 severity missing/unknown
Should have 30-day follow-up but doesn't

Major problems (+5 points per problem)

High levels of missingness
High levels of unknowns

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626 **APPENDIX B: Breast Cancer Disparities Statistical Analysis Plan:**

627

628 Approved Project Title: **Racial and Ethnic Disparities among Patients with Breast Cancer and COVID-19 in CCC19**
629 **Cohort**

630

631

632 Project Team Leads: Gayathri Nagaraj, Melissa Accordino, Maryam Lustberg, Dimpy Shah

633

634 Name of the investigator completing this survey: Gayathri Nagaraj and Melissa Accordino

635

636 Proposed milestone deadline for this manuscript:

637 • Abstract submission for ASCO 2021, deadline February 17 completed.

638 • ASCO abstract accepted for oral presentation. Deadlines for prelim slide upload May 7, and final deadline for
639 uploading slides May 14.

640 • Manuscript preparation simultaneously, deadline and journal TBD

641 Do you have local statistical support: No

642

643 Name and emails of (at most) 2 additional project team members who would like to be part of the analysis team for the
644 project:

645 Melissa Accordino, Email: mkg2134@cumc.columbia.edu

646 Maryam Lustberg, Email: Maryam.Lustberg@osumc.edu

647 Dimpy Shah, Email: shahdp@uthscsa.edu

648

649 Initial draft of the Statistical Analysis Plan (SAP), following STROBE guidelines, for our review and input. Please complete
650 sections 1 and 3-11 (and 12 if you have local statistical support)

651

652 **1 (a) Manuscript Title:** **Racial and Ethnic Disparities among Patients with Breast Cancer and COVID-19 in CCC19**
653 **Cohort**

654

655 **1 (b) Provide in the abstract an informative and balanced summary of what was done and what will be found.**

656

657 Racial and Ethnic minority subgroups are at a disproportionately increased risk of contracting COVID-19 or experiencing
658 severe illness regardless of age. Racial and Ethnic disparities also affect breast cancer incidence and mortality. The impact of
659 COVID-19 on patients with breast cancer is largely unknown but is currently under investigation. Outcomes of COVID-19
660 specifically in racial and ethnic minority patients with active or prior history of breast cancer is currently unknown.

661 **3. Objectives**

662 State specific objectives, including any prespecified hypotheses:

663

664 **The overarching goal** of this study is to evaluate the racial and ethnic disparities related to COVID-19 outcomes, in patients
665 with active or previous history of breast cancer. To evaluate this, the following specific aims are proposed:

666

- 667 • **Specific Aim 1: To compare the distribution of major clinical, sociodemographic, and breast cancer risk**
668 **factors among racial and ethnic subgroups of women with active or previous history of single primary**
669 **invasive breast cancer diagnosed with COVID-19.**

670 We *hypothesize* that racial and ethnic minority women with breast cancer are more likely to have active comorbid
671 conditions, such as diabetes mellitus, obesity, smoking history, and a baseline lower performance status compared to
672 non-Hispanic white (NHW) women with active or previous history of breast cancer diagnosed with COVID-19.
673 Other variables of interest are age, month/year of COVID-19 diagnosis, area of patient residence, geographic region,
674 insurance type, treatment center characteristics, receipt of anti-COVID-19 treatment along with tumor characteristics
675 including breast cancer biologic subtype, cancer status, treatment intent, timing of anti-cancer treatment and
676 modality of anti-cancer treatment.

677

- 678 • **Specific Aim 2: To compare COVID-19 clinical outcomes on a five-level ordinal scale based on patient's most**
679 **severe reported outcomes: no complications (uncomplicated); hospital admission, intensive care unit (ICU)**
680 **admission, mechanical ventilation; or death from any cause in racial and ethnic minority subgroups of**
681 **women with previous or active history of breast cancer compared to NHW adjusted for baseline**
682 **characteristics. We also plan to evaluate the death within 30 days of COVID-19 diagnosis among racial and**
683 **ethnic subgroups of women with previous or active history of breast cancer compared to NHW adjusted for**
684 **baseline characteristics.**

685 We *hypothesize* that there will be higher rates of severe COVID-19 related outcomes in the racial and ethnic
686 minority subgroups compared to non-Hispanic white (NHW) patients with active or previous history of breast
687 cancer.

688

- 689 • **Exploratory aims:**

690

- 691 1. To evaluate the frequency of hospitalization, supplemental oxygen use, ICU admission and use of
692 mechanical ventilation in the various racial ethnic groups.
693 2. To describe the distribution of major clinical, sociodemographic, breast cancer risk factors and outcomes in
694 men with active or previous history of breast cancer diagnosed with COVID-19.
695 3. Assess the rate of major clinical complications such as cardiovascular, pulmonary, gastrointestinal,
696 superimposed infection, vascular thrombosis and others among various racial and ethnic groups of women
697 with active or previous history of breast cancer.

698

699 **4. Study Design**

700 Study Design:

701 Present key elements of study design early in the paper

702 This is a retrospective cohort study using de-identified data from the COVID-19 and Cancer Consortium (CCC19) database
703 which is a centralized multi-institution registry of patients with current or past history of cancer diagnosed with COVID-19.
704 Study data are collected and managed using REDCap software hosted at Vanderbilt University Medical Center.

705

706

707 **5. Setting**

708 **Setting**

709 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.

710 The CCC19 international registry consists of de-identified data on adult patients (18 years and older) with a current or past
711 history of hematologic malignancy or invasive solid tumor who either have laboratory-confirmed SARS-CoV-2 infection or
712 presumptive diagnosis of COVID-19. The CCC19 registry includes patients with either active cancer or a history of cancer
713 and contains variables related to patient demographics, cancer history, and COVID-19 clinical course including receipt of
714 COVID-19 related therapeutics along with follow-up data. The member institutions of the consortium report data through the
715 online REDCap data collection survey developed by CCC19. Data collection period is ongoing, for the purpose of this
716 analysis, the data collected from March 17, 2020 to February 9 2021 will be used.

717 **6. Participants**

718 (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up:

719

720 Patients with active or previous history of invasive breast cancer with evaluable self-reported race/ethnicity data, and with
721 laboratory confirmed COVID-19 will be our study population. While the primary analysis will be restricted to women with
722 active or previous history of breast cancer and descriptive data on men with active or previous history of breast cancer will be
723 provided separately as part of the exploratory analysis given the small numbers. We will restrict our analysis to patients
724 diagnosed in the United States of America since the racial and ethnic disparities of interest have been previously described in
725 United States. We will also exclude patients who have multiple malignancies including a history of bilateral breast cancer
726 with the exception of contralateral DCIS only. Further, patients who are not evaluable for the primary ordinal outcome or
727 with a data quality score >4 will be excluded. For this analysis, the unknown/Not reported category of race and ethnicity will
728 be excluded.

729

730

731

732

733

734

735

736

737

738

739


740

741

742

743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774

CONSORT flow diagram



775 (b) For matched studies, give matching criteria and number of exposed and unexposed:

776

777 Not applicable as the CCC19 registry does not carry data for cancer patients who are not exposed to Covid-19.

778

779 **7. Variables (Clearly define all variables)**

780 **Outcomes:**

- 781 • Primary: COVID-19 severity outcome defined on a five-level ordinal scale based on patient's most severe reported
- 782 outcomes: No complications (uncomplicated); hospital admission; intensive care unit admission, mechanical
- 783 ventilation; or death from any cause.
- 784 • Secondary: 30-day all-cause mortality
- 785 • Exploratory/Descriptive:
- 786 ○ Rates of hospitalization; oxygen requirements; ICU admission; mechanical ventilation.
- 787 ○ Major clinical complications (cardiovascular, pulmonary, gastrointestinal, AKI, MOF, superimposed
- 788 infection, sepsis, any bleeding, DIC, Thrombosis).
- 789 ○ Descriptive statistics for men with breast cancer diagnosed with COVID-19.

790

791 **Exposures**

792 **Predictors**

- 793 1) Self-reported race
- 794 2) Self-reported ethnicity

795 **Potential confounders**

796 **Higher priority**

- 797 1) Age in years
- 798 2) Obesity (obese, not obese)
- 799 3) Co-morbidities (pulmonary, cardiovascular, renal, diabetes mellitus)
- 800 4) ECOG PS (0, 1, ≥ 2 , unknown)
- 801 5) Receptor status (Hormone receptor positive, HER2 positive, dual positive, Triple negative)
- 802 6) Cancer status (remission < 5 years, remission > 5 years, active stable, active responding, active progressing,
- 803 unknown)
- 804 7) Timing of anti-cancer treatment (never treated, 0-4 weeks, 1-3 months, >3 months)
- 805 8) Modality of recent anti-cancer treatment (none, cytotoxic chemotherapy, targeted therapy, endocrine therapy,
- 806 immunotherapy, locoregional therapy, other)
- 807 9) Period of COVID-19 diagnosis (Jan-April 2020, May-August 2020, Sep-Nov 2020, Dec 2020-Feb 2021)

808

809 **Lower priority**

- 810 10) Smoking (ever, never)
- 811 11) US region of patient residence (NE, MW, South, West)
- 812 12) Area of patient residence (urban, suburban, rural)
- 813 13) Insurance status (Not insured, private insurance, Medicaid/Medicare, other government, missing/unknown)
- 814 14) Treatment center characteristics academic (university, tertiary and NCI designated comprehensive cancer centers),
- 815 community (practice and hospital), other.

816

817

818 **Effect modifiers**

819 **None**

820 Diagnostic criteria (if applicable)

821 8. Data Sources / Measurement

822 For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe
823 comparability of assessment methods if there is more than one group.

824

825 9. Bias

826 Describe any efforts to address potential sources of bias

827 Multivariable regression models will be used to adjust for known confounding variables.

828

829 10. Study size

830 Explain how the study size was arrived at

831 Study size is based on the number of breast cancer cases reported in the registry at the time of Analysis. Breast cancer is the
832 single largest solid tumor cohort within the CCC19 registry accounting for roughly 21% of cases. The numbers are expected
833 to rise given the steep accrual rate.

834

835 11. Quantitative variables

836 Explain how quantitative variables will be handled in the analyses. If applicable, describe which groupings will be chosen
837 and why

838

839 12. Statistical methods

840 (a) Describe all statistical methods, including those to be used to control for confounding

841

842 *Primary analysis among women:*

843 Standard descriptive statistics will summarize major clinical, demographic, and breast cancer prognostic factors; clinical
844 complications during hospitalization; and rates of 30-day mortality, hospitalization, oxygen requirement, ICU admission, and
845 mechanical ventilation among racial and ethnic subgroups. Multivariable ordinal and binary logistic regression models will
846 estimate differences in adjusted odds of COVID-19 severity and 30-day mortality, respectively, between racial and ethnic
847 subgroups. Because the ordinal outcome is assessed over patient's total follow-up period, the model will include an offset for
848 (log) follow-up time. Adjustment covariates will be selected first from the "higher priority" confounders listed above,
849 followed by those listed as "lower priority." Coefficients and standard errors from models with different levels of adjustment,
850 variance inflation factors, and clinical judgement will be used to assess model stability.

851

852 *Descriptive analysis among men:*

853 We will calculate standard descriptive statistics for major clinical, demographic, and breast cancer prognostic factors and
854 clinical complications during hospitalization; rates of 30-day mortality, hospitalization, oxygen requirement, ICU admission,
855 and mechanical ventilation among men with active or previous history of breast cancer.

856

857
858 (b) Describe any methods that will be used to examine subgroups and interactions

859 None included.

860

861 (c) Explain how missing data will be addressed

862 Multiple imputation will be used to impute missing and unknown data for all variables included in the analysis, with some
863 exceptions: unknown ECOG performance score and unknown cancer status will not be imputed and treated as a separate
864 category in analyses. Imputation will be performed on the largest dataset possible (that is, after removing test cases and other
865 manual exclusions, but before applying specific exclusion criteria). At least 10 imputed datasets will be used.

866

867 (d) If applicable, explain how loss to follow-up will be addressed

868 All observed outcomes will be used with models adjusted for duration of follow-up.

869

870 (e) Describe any sensitivity analyses

871 None.

872

873

874

875

876

877

878

879

880

881

882

883

884

885

886

887

888

889

890

891

892

893

894 **APPENDIX C: CCC19 Approved Project Variables**

895 *Primary Outcome (Table III)*

Outcome description	Outcome variable name	Outcome values
Custom ordinal outcome with death at any time	<i>der_ordinal_v1a</i>	0 = not hospitalized; 1 = hospitalized; 2 = ICU; 3 = mechanical ventilation; 4 = death at any time
Follow-up in days, with some estimation for intervals	<i>der_days_fu</i>	Integer (days)

896

897 *Secondary Outcome (Table II)*

Outcome description	Outcome variable name	Outcome values	Additional Details
Derived dead/alive variable	<i>der_deadbinary</i>	0 = No; 1 = Yes; 99 = Unknown	
Derived variable indicating whether patient has died within 30 days of COVID-19 diagnosis (default = No)	<i>der_dead30</i>	0 = No; 1 = Yes; 99 = Unknown	
Derived variable indicating whether patients required mechanical ventilation	<i>der_mv</i>	0 = No; 1 = Yes; 99 = Unknown	
Derived variable indicating time in ICU	<i>der_ICU</i>	0 = No; 1 = Yes; 99 = Unknown	
Derived hospitalized/not hospitalized variable	<i>der_hosp</i>	0 = No; 1 = Yes; 99 = Unknown	
Derived cardiovascular complication variable (see additional details)	<i>der_CV_event_v2</i> (<i>der_any_CV</i> is the variable name in R script)	0 = No; 1 = Yes; 99=Unknown.	<p>Derived with the following derived variables:</p> <ul style="list-style-type: none"> <i>der_hotn_comp</i>, <i>der_MI_comp</i>, <i>der_card_isch_comp</i>, <i>der_AFib_comp</i>, <i>der_VF_comp</i>, <i>der_arry_oth_comp</i>, <i>der_CMY_comp</i>, <i>der_CHF_comp</i>, <i>der_PE_comp</i>, <i>der_DVT_comp</i>, <i>der_stroke_comp</i>, <i>der_thrombosis_NOS_comp</i> <p>Coded as 1 if any of these variables is 1; coded as 0 if all these variables are 0; coded as 99 if any of variables is 99 and <i>der_CV_event_v2</i> is missing;</p>

			otherwise, NA For all listed variable here: 0=No, 1=Yes, 99=Unknown
Derived pulmonary complication variable (see additional details)	der_pulm_event (der_any_Pulm is the variable name in R script)	0 = No; 1 = Yes; 99=Unknown.	Derived with the following derived variables: der_resp_failure_comp, der_pneumonitis_comp, der_pneumonia_comp, der_ARDS_comp, der_PE_comp, der_pleural_eff_comp, der_empyema_comp Coded as 1 if any of these variables is 1; coded as 0 if all these variables are 0; coded as 99 if any of variables is 99 and der_pulm_event is missing; otherwise, NA For all listed variable here: 0=No, 1=Yes, 99=Unknown
Derived gastrointestinal complication variable (see additional details)	der_GI_event (der_any_Gast is the variable name in R script)	0 = No; 1 = Yes; 99=Unknown.	Derived with the following derived variables: der_AHI_comp, der_ascites_comp, der_BO_comp, der_bowelPerf_comp, der_ileus_comp, der_peritonitis_comp Coded as 1 if any of these variables is 1; coded as 0 if all these variables are 0; coded as 99 if any of variables is 99 and der_GI_event is missing; otherwise, NA For all listed variable here: 0=No, 1=Yes, 99=Unknown
Acute kidney injury (checkbox only)	der_AKI_comp	0 = No; 1 = Yes; 99 = Unknown	
Multisystem organ failure	der_MOF_comp	0 = No; 1 = Yes; 99 = Unknown	
Any co-infection within +/- 2 weeks of COVID-19 dx	der_coinfection_any	0 = No; 1 = Yes; 99 = Unknown	
Sepsis	der_sepsis_comp	0 = No; 1 = Yes; 99 = Unknown	
Bleeding	der_bleeding_comp	0 = No; 1 = Yes; 99 = Unknown	
DIC (without modifier of	der_DIC_comp	0 = No; 1 = Yes; 99 =	

definite/probable/possible)		Unknown	
Remdesivir as treatment for COVID-19 ever	der_rem	0 = No; 1 = Yes; 99 = Unknown	
Hydroxychloroquine as COVID-19 treatment ever	der_hcq	0 = No; 1 = Yes; 99 = Unknown	
Steroids as COVID-19 treatment ever	der_steroids_c19	0 = No; 1 = Yes; 99 = Unknown	
COVID-19 treatments other than HCQ, steroids, remdesivir	der_other_tx_c19_v2	0 = No; 1 = Yes; 99 = Unknown	
Indicates whether patient has ever had supplemental o2	der_o2_ever	0 = No; 1 = Yes; 99 = Unknown	

898
899
900

Covariate description	Variable name	Covariate values	Additional Details
Race/ethnicity including Asian	der_race_v2	Hispanic; Non-Hispanic AAPI; Non-Hispanic Black; Non-Hispanic White; Other	
Age with imputation for categoricals	der_age_trunc	Years (continuous 18-89; patients noted to be greater than 89 are set to be age = 90)	
Insurance type	der_insurance	Medicaid alone; Medicare alone; Medicare/Medicaid +/- other; Other government +/- other; Private +/- other; Uninsured; Unknown	
Derived variable for smoking status collapsing the current/former smoker variables	der_smoking2	Never; Current or Former; Unknown	
Binary obesity (BMI \geq 30 or checkbox checked) indicator	der_obesity	0 = No; 1 = Yes; 99 = Unknown	
Cardiovascular comorbidity (CAD, CHF, Afib, arrhythmia NOS, PVD, CVA, cardiac disease NOS)	der_card	0 = No; 1 = Yes; 99 = Unknown	
Derived variable indicating whether patient has pulmonary comorbidities	der_pulm	0 = No; 1 = Yes; 99 = Unknown	
Renal comorbidities	der_renal	0 = No; 1 = Yes; 99 =	

		Unknown	
Derived variable indicating whether patient has diabetes mellitus	der_dm2	0 = No; 1 = Yes; 99 = Unknown	
Performance Status	der_ecogcat2	ECOG 0, 1, or 2+	
Breast biomarkers combined variable	der_breast_biomarkers	1 = ER+; 2 = ER+/HER2+; 3 = HER2+; 4 = triple negative; 99 = Unknown	
Derived variable indicating cancer status (Splits remission/NED by cancer timing)	der_cancer_status_v4	0 - Remission/NED, remote; 1 - Remission/NED, recent; 2 - Active, responding; 3 - Active, stable; 4 - Active, progressing; 99 - Unknown	
Timing of cancer treatment relative to COVID-19, collapsed	der_cancer_tx_timing_v2	0 = more than 3 months; 1 = 0-4 weeks; 2 = 1-3 months (*); 88 = never or after COVID-19 diagnosis; 99 = unknown	
No cancer treatment in the 3 months prior to COVID-19	der_cancertr_none	0=No; 1=Yes; 99=Unknown	Derived with the following covariates: der_any_cyto, der_any_targeted, der_any_endo, der_any_immuno, der_any_local, der_any_other Coded as 1 if all these variables are 0; coded as 0 if any of these variables is 1; coded as 99 if any of these variables is 99; otherwise, NA
Any cytotoxic cancer treatment in the 3 months prior to COVID-19	der_any_cyto	0 = No; 1 = Yes; 99 = Unknown	
Any targeted therapy in the 3 months prior to COVID-19	der_any_targeted	0 = No; 1 = Yes; 99 = Unknown	
Any targeted therapy includes an anti-HER2 therapy in the 3 months prior to COVID-19	der_her2_3m	0 = No; 1 = Yes	Derived with der_her2, der_any_targeted. Coded as 1 if der_any_targeted is 1 and der_her2 is 1 Coded as 0 if: a. der_any_targeted is 1 and der_her2 is 0 b. der_any_targeted is 1 Otherwise, NA

			<p>der_her2: 0 = No; 1 = Yes</p>
<p>Any targeted therapy includes a CDK4/6 inhibitor therapy in the 3 months prior to COVID-19</p>	der_cdk46i_3m	0 = No; 1 = Yes	<p>Derived with der_cdk46i, der_any_targeted.</p> <p>Coded as 1 if der_any_targeted is 1 and der_cdk46i is 1</p> <p>Coded as 0 if: a. der_any_targeted is 1 and der_cdk46i is 0 b. der_any_targeted is 1</p> <p>Otherwise, NA</p> <p>der_cdk46i: 0 = No; 1 = Yes</p>
<p>Any other targeted therapy (Not anti-HER2 / CDK4/6 inhibitor) in the 3 months prior to COVID-19</p>	der_other_3m	0 = No; 1 = Yes	<p>Derived with der_targeted_not_her2_cdk46i, der_any_targeted.</p> <p>Coded as 1 if der_any_targeted is 1 and der_targeted_not_her2_cdk46i is 1</p> <p>Coded as 0 if: a. der_any_targeted is 1 and der_targeted_not_her2_cdk46i is 0 b. der_any_targeted is 1</p> <p>Otherwise, NA</p> <p>der_targeted_not_her2_cdk46i: 0 = No; 1 = Yes</p>
<p>Any endocrine therapy in the 3 months prior to COVID-19</p>	der_any_endo	0 = No; 1 = Yes; 99 = Unknown	
<p>Any immunotherapy in the 3 months prior to COVID-19</p>	der_any_immuno	0 = No; 1 = Yes; 99 = Unknown	
<p>Any local therapy (surgery or RT) within 3 months</p>	der_any_local	0 = No; 1 = Yes; 99 = Unknown	
<p>Any other cancer therapy in the 3 months prior to COVID-19</p>	der_any_other	0 = No; 1 = Yes; 99 = Unknown	
<p>Region of patient residence with ex-US collapsed</p>	der_region_v2	Non-US; Other; Undesignated US; US Midwest; US Northeast; US South; US West	
<p>Trimester and year of</p>	der_tri_rt_dx	T1 2020; T2 2020; T3	

diagnosis, using the most recent side of the interval as anchor		2020; T1 2021	
What type of area does the patient primarily reside in?	urban_rural ¹	1, Urban (city) 2, Suburban (town, suburbs) 3, Rural (country) 88, Other 99, Unknown	
The type of health care center providing the patient's data	der_site_type	AMC = academic medical center; CP = community practice; TCC = tertiary care center	
Initial Severity and Course of Illness	severity_of_covid_19_v2 ¹	1, Mild (no hospitalization required) 2, Moderate (hospitalization indicated) 3, Severe (ICU admission indicated) 99, Unknown	
Derived treatment intent	der_tr_intent	Unknown Treatment; Not on Treatment; Palliative; Curative; Missing Unknown Treatment and Missing were collapsed for analysis	Derived with der_anytx and treatment_intent: Coded as "Unknown Treatment" if der_anytx is NA or 99; Coded as "Not on Treatment" if der_anytx is 0 Coded as "Palliative" if der_anytx is 1 and treatment_intent is 2 Coded as "Curative" if der_anytx is 1 and treatment_intent is 1 Otherwise, Missing der_anytx: 0 = No; 1 = Yes; 99 = Unknown Treatment_intent: 1, Curative 2, Palliative 99, Unclear or unknown
Most recent line of cancer treatment, including systemic and non-systemic therapies	der_txline	Untreated in last 12 months; Curative NOS; First line; Non-curative NOS; Other; Second line or greater; Unknown	
Hematologic malignancy indicator	der_heme	0 = No; 1 = Yes	

901

Other covariate related to cohort selection for analysis	Variable name	Covariate values	Covariate description
Sex (Recode other/prefer not to	der_sex	Male, Female	

say gender --> missing)			
Breast cancer	der_Breast	0 = No; 1 = Yes	
Cancer type of second malignancy. If the patient has more than two malignancies, please select the second-most recently diagnosed cancer type. If unknown or unclear, please specify in the free text box below	cancer_type_2 ¹	** indicates no second malignancy.	
Region of patient residence with US and ex-US collapsed	der_region_v3	Non-US; Other; US	

902


903 New covariate request – 2-5-22

New covariate	Variable name	Covariate values	Covariate description
MBC vs non-MBC	der_metastatic	0 = No; 1 = Yes; 99 = Unknown	Metastatic cancer status (only applicable to solid tumors/lymphoma)
MBC site of metastasis	der_met_bone	0 = No; 1 = Yes; 99 = Unknown	Metastatic to bone
MBC site of metastasis	der_met_liver	0 = No; 1 = Yes; 99 = Unknown	Metastatic to liver
MBC site of metastasis	der_met_lung_v2	0 = No; 1 = Yes; 99 = Unknown	Metastatic to lung

904

905

906 **APPENDIX D: Supplementary Figure I - Proportional Odds Assumption**



907
908
909
910
911
912
913
914

915 **APPENDIX E**

Supplement Table 1. Unadjusted rates of outcomes after COVID-19 diagnosis by cancer status							
	NED>5 Years	NED<5 Years	Active and Responding	Active and Stable	Active and Progressing	Missing/ Unknown	Total
	n^a (%)	n^a (%)	n^a (%)	n^a (%)	n^a (%)	n^a (%)	n^a (%)
Outcomes							
Total all-cause mortality ^b	40 (11)	12 (3)	12 (7)	11 (7)	37 (38)	11 (9)	123 (9)
30-day all-cause mortality ^c	29 (8)	10 (2)	10 (6)	4 (2)	27 (28)	9 (7)	89 (6)
Received mechanical ventilation ^b	20 (5)	13 (3)	9 (5)	7 (4)	12 (12)	8 (7)	69 (5)
Admitted to an intensive care unit ^b	35 (10)	25 (6)	13 (8)	8 (5)	18 (19)	12 (10)	111 (8)
Admitted to the hospital ^b	163 (43)	129 (29)	54 (31)	57 (34)	70 (72)	39 (32)	512 (37)
^a N is based on non-missing data							
^b Included in primary ordinal COVID-19 severity outcome.							
^c Secondary outcome.							

916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935

936 **APPENDIX F**

937

Supplementary Table IIA: Baseline characteristics of female patients with MBC	
MBC (N=233)	
Age, years^a	
Median [IQR]	58.0 [49.8, 68.3]
Race/Ethnicity	
Non-Hispanic White	107 (46%)
Non-Hispanic Black	56 (24%)
Hispanic	50 (21%)
Non-Hispanic AAPI	10 (4%)
Other	10 (4%)
Smoking Status	
Never	162 (70%)
Current or Former	66 (28%)
Missing/unknown	5 (2%)
Obesity	
No	139 (60%)
Yes	93 (40%)
Comorbidities^b	
Cardiovascular	42 (18%)
Pulmonary	37 (16%)
Renal Disease	16 (7%)
Diabetes mellitus	52 (22%)
Missing/unknown	3 (1%)
ECOG Performance Status	
0	63 (27%)
1	84 (36%)
2+	42 (18%)
Unknown	44 (19%)
Missing	0 (0%)
Receptor status	
HR+/HER2-	98 (42%)
HR+/HER2+	53 (23%)
HR-/HER2+	26 (11%)
Triple Negative	33 (14%)
Missing/unknown	23 (10%)
Cancer Status	

Active and responding	55 (24%)
Active and stable	78 (33%)
Active and progressing	74 (32%)
Unknown	25 (11%)
Missing	0 (0%)
Metastatic sites (MBC)	
Lung	65 (28%)
Bone	135 (58%)
Liver	61 (26%)
Missing/unknown	19 (8%)
Timing of anti-cancer therapy	
Never/After COVID-19	X*
0-4 weeks	189 (81%)
1-3 months	14 (6%)
>3 months	19 (8%)
Missing/unknown	11 (5%)*
Modality of active anti-cancer therapy^{b,c}	
None	24 (10%)
Cytotoxic Chemotherapy	114 (49%)
Targeted Therapy	115 (49%)
Endocrine Therapy	98 (42%)
Immunotherapy	17 (7%)
Local (Surgery/Radiation)	27 (12%)
Other	6 (3%)
Missing/unknown	6 (3%)
Region	
Northeast	97 (42%)
Midwest	44 (19%)
South	34 (15%)
West	56 (24%)
Undesignated	2 (1%)
Period of COVID-19 diagnosis	
Jan-Apr 2020	33 (14%)
May-Aug 2020	101 (43%)
Sept-Dec 2020	52 (22%)
Jan-Aug 2021	45 (19%)
Missing/unknown	2 (1%)
Area of patient residence	
Urban	103 (44%)
Suburban	80 (34%)
Rural	12 (5%)
Missing/unknown	38 (16%)
Treatment center characteristics	

Academic Medical Center	43 (18%)
Community Practice	63 (27%)
Tertiary Care Center	127 (55%)
Missing/unknown	0 (0%)
Severity of COVID19	
Mild	126 (54%)
Moderate	93 (40%)
Severe	13 (6%)
Missing/Unknown	1 (<1%)
*Cells combined to mask N<5 according to CCC19 low count policy	
^a Age was truncated at 90 years.	
^b Percentages could sum to >100% because categories are not mutually exclusive.	
^c Within 3 months of COVID-19 diagnosis.	

938

Supplement Table IIB: Unadjusted rates of outcomes after COVID-19 diagnosis in females with MBC

	n ^f (%)
Outcomes	
Total all-cause mortality ^a	45 (19)
30-day all-cause mortality ^b	28 (12)
Received mechanical ventilation ^a	20 (9)
Admitted to an intensive care unit ^a	29 (12)
Admitted to the hospital ^a	124 (53)
Clinical Complications	
Any cardiovascular complication ^c	48 (21)
Any pulmonary complication ^d	86 (37)
Any gastrointestinal complication ^e	13 (6)
Acute kidney injury	32 (14)
Multisystem organ failure	12 (5)
Superimposed infection	32 (14)
Sepsis	28 (12)
Any bleeding	8 (3)
Interventions	
Remdesivir	35 (15)
Hydroxychloroquine	25 (11)
Corticosteroids	65 (29)
Covid Other	45 (20)
Supplemental oxygen	84 (37)
^a Included in primary ordinal COVID-19 severity outcome	
^b Secondary outcome	
^c Cardiovascular complication includes hypotension, myocardial infarction, other cardiac ischemia, atrial fibrillation, ventricular fibrillation, other cardiac arrhythmia, cardiomyopathy, congestive heart failure, pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, thrombosis NOS complication.	
^d Pulmonary complication includes respiratory failure, pneumonitis, pneumonia, acute respiratory distress syndrome (ARDS), PE, pleural effusion, empyema.	
^e Gastrointestinal complication includes acute hepatic injury, ascites, bowel obstruction, bowel perforation, ileus, peritonitis	
^f N is based on non-missing data	

939
940
941
942
943
944
945
946

APPENDIX G

Supplement Table III: Adjusted Associations of Race Factors with COVID-19 Severity Outcome.			
Race (Ref: NHW)	COVID-19 severity		
	OR (95% CI)	Point Value E estimates ^a	Lower bound E values ^a
Black	1.74 (1.24- 2.45)	1.97	1.47
Hispanic	1.38 (0.93- 2.05)	1.63	1.00
AAPI	3.40 (1.70- 6.79)	3.09	1.93
Other	2.97 (1.71- 5.17)	2.84	1.94

^aThese values were calculated based on the formula for logistic regression

947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969 **APPENDIX H:**

Supplement Table IVA: Male patients with breast cancer and COVID-19: Baseline Characteristics	
Total	25 (100%)
Age, years^a	
Median [IQR]	67.0 [60 - 75]
Race/Ethnicity	
NHW	13 (52%)
Black	8 (32%)
Hispanic	<5 (<20%)
AAPI	0 (0%)
Other	<5 (<20%)
Smoking Status	
Never	18 (72%)
Current or Former	7 (28%)
Obesity	
No	12 (48%)
Yes	13 (52%)
Comorbidities^b	
Cardiovascular	6 (24%)
Pulmonary	5 (20%)
Renal Disease	<5 (<20%)
Diabetes mellitus	11 (44%)
ECOG Performance Status	
0	5 (20%)
1	10 (40%)
2+	X*
Unknown	10 (40%)*
Receptor status	
HR+/HER2-	18 (72%)
HR+/HER2+	5 (20%)
HR+/HER2+	X*
Triple Negative	0 (0%)
Missing/unknown	2 (8%)*
Cancer Status	
Remission or NED, >5 years	<5 (<20%)
Remission or NED, <5 years	6 (24%)
Active and responding	<5 (<20%)
Active and stable	<5 (<20%)
Active and progressing	5 (20%)

Unknown	3 (12%)
Timing of anti-cancer therapy	
Never/After COVID-19	<5 (<20%)
0-4 weeks	17 (68%)
1-3 months	0 (0%)
>3 months	<5 (<20%)
Missing/unknown	1 (4%)
Modality of active anti-cancer therapy^{b,c}	
None	7 (28%)
Chemotherapy	6 (24%)
Targeted Therapy	6 (24%)
Endocrine Therapy	10 (40%)
Immunotherapy	0 (0%)
Local (Surgery/Radiation)	<5 (<20%)
Other	0 (0%)
Missing/unknown	1 (4%)
Region	
Northeast	11 (44%)
Midwest	<5 (<20%)
South	<5 (<20%)
West	7 (28%)
Undesignated	0 (0%)
Period of COVID-19 diagnosis	
Jan-Apr 2020	10 (40%)
May-Aug 2020	9 (36%)
Sept-Dec 2020	5 (20%)
Area of patient residence	
Urban	9 (36%)
Suburban	8 (32%)
Rural	0 (0%)
Missing/unknown	8 (32%)
Severity of COVID19	
Mild	11 (44%)
Moderate/Severe	14 (56%)
*Cells combined to mask N<5 according to CCC19 low count policy	
^a Age was truncated at 90 years.	
^b Percentages could sum to >100% because categories are not mutually exclusive.	
^c Within 3 months of COVID-19 diagnosis.	
Variable Categories with one to five cases are masked by replacing with N < 5 according to CCC19 policy	

Suppl Table IVB: Unadjusted rates of outcomes after COVID-19 diagnosis among males with BC	
Outcomes	
Total all-cause mortality	5 (20)
30-day all-cause mortality	5 (20)
Received mechanical ventilation	<5 (<20%)
Admitted to an intensive care unit	<5 (<20%)
Admitted to the hospital	15 (60)
Clinical Complications	
Any cardiovascular complication ^a	<5 (<20%)
Any pulmonary complication ^b	12 (48)
Any gastrointestinal complication ^c	0 (0%)
Acute kidney injury	<5 (<20%)
Multisystem organ failure	<5 (<20%)
Superimposed infection	<5 (<20%)
Sepsis	<5 (<20%)
Any bleeding	<5 (<20%)
Interventions	
Remdesivir	<5 (<20%)
Hydroxychloroquine	7 (28)
Corticosteroids	<5 (<20%)
Other	9 (36)
Supplemental oxygen	12 (48)
Variable Categories with one to five cases are masked by replacing with N < 5 according to CCC19 policy	
^a Cardiovascular complication includes hypotension, myocardial infarction, other cardiac ischemia, atrial fibrillation, ventricular fibrillation, other cardiac arrhythmia, cardiomyopathy, congestive heart failure, pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, thrombosis NOS complication.	
^b Pulmonary complication includes respiratory failure, pneumonitis, pneumonia, acute respiratory distress syndrome (ARDS), PE, pleural effusion, empyema.	
^c Gastrointestinal complication includes acute hepatic injury, ascites, bowel obstruction, bowel perforation, ileus, peritonitis	

972 **APPENDIX I:**

973 **List of Participants by Institution**

974 Alphabetical list of participants by institution that contributed at least one record to the analysis.

975 **Bolded** = site PI/co-PIs; site co-investigators are listed alphabetically by last name.

- 976 • **Balazs Halmos, MD; Amit Verma, MBBS**; Benjamin A. Gartrell, MD; Sanjay Goel, MBBS; Nitin Ohri, MD; R.
977 Alejandro Sica, MD; Astha Thakkar, MD (Albert Einstein College of Medicine, Montefiore Medical Center, Bronx,
978 NY, USA)
- 979 • **Keith E. Stockerl-Goldstein, MD**; Omar Butt, MD, PhD; Jian Li Campian, MD, PhD; Mark A. Fiala, MSW;
980 Jeffrey P. Henderson, MD, PhD; Ryan S. Monahan, MBA; Alice Y. Zhou, MD, PhD (Alvin J. Siteman Cancer
981 Center at Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO, USA)
- 982 • **Michael A. Thompson, MD, PhD, FASCO**; Pamela Bohachek, RN, CCRC; Daniel Mundt, MD; Mitrianna
983 Streckfuss, MPH; Eyob Tadesse, MD (Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI, USA)
- 984 • **Philip E. Lammers, MD, MSCI** (Baptist Cancer Center, Memphis, TN, USA)
- 985 • **Sanjay G. Revankar, MD, FIDSA** (The Barbara Ann Karmanos Cancer Institute at Wayne State University School
986 of Medicine, Detroit, MI, USA)
- 987 • **Jaymin M. Patel, MD**; Andrew J. Piper-Vallillo, MD; Poorva Bindal, MBBS (Beth Israel Deaconess Medical
988 Center, Boston, MA, USA)
- 989 • **Orestis A. Panagiotou, MD, PhD**; Pamela C. Egan, MD; Dimitrios Farmakiotis, MD, FACP, FIDSA; Hina Khan,
990 MD; Adam J. Olszewski, MD (Brown University and Lifespan Cancer Institute, Providence, RI, USA)
- 991 • **Arturo Loaiza-Bonilla, MD, MSED, FACP** (Cancer Treatment Centers of America, AZ/GA/IL/OK/PA, USA)
- 992 • **Salvatore A. Del Prete, MD**; Michael H. Bar, MD, FACP; Anthony P. Gulati, MD; K. M. Steve Lo, MD; Suzanne
993 J. Rose, MS, PhD, CCRC, FACRP; Jamie Stratton, MD; Paul L. Weinstein, MD (Carl & Dorothy Bennett Cancer
994 Center at Stamford Hospital, Stamford, CT, USA)
- 995 • **Robin A. Buerki, MD**; Jorge A. Garcia, MD, FACP (Case Comprehensive Cancer Center at Case Western Reserve
996 University/University Hospitals, Cleveland, OH, USA)
- 997 • **Shilpa Gupta, MD**; Nathan A. Pennell, MD, PhD, FASCO; Manmeet S. Ahluwalia, MD, FACP; Scott J. Dawsey,
998 MD; Christopher A. Lemmon, MD; Amanda Nizam, MD (Cleveland Clinic, Cleveland, OH, USA)
- 999 • **Claire Hoppenot, MD; Ang Li, MD, MS** (Dan L Duncan Comprehensive Cancer Center at Baylor College of
1000 Medicine, Houston, TX, USA)
- 1001 • **Toni K. Choueiri, MD**; Ziad Bakouny, MD, MSc; Jean M. Connors, MD; George D. Demetri, MD, FASCO; Dory
1002 A. Freeman, BS; Antonio Giordano, MD, PhD; Chris Labaki, MD; Alicia K. Morgans, MD, MPH; Anju Nohria,
1003 MD; Andrew L. Schmidt, MD; Eliezer M. Van Allen, MD; Pier Vitale Nuzzo, MD, PhD; Wenxin (Vincent) Xu,
1004 MD; Rebecca L. Zon, MD (Dana-Farber Cancer Institute, Boston, MA, USA) (Dana-Farber Cancer Institute,
1005 Boston, MA, USA)
- 1006 • **Susan Halabi, PhD, FASCO**; Tian Zhang, MD, MHS (Duke Cancer Institute at Duke University Medical Center,
1007 Durham, NC, USA)
- 1008 • **John C. Leighton Jr, MD, FACP** (Einstein Healthcare Network, Philadelphia, PA, USA)
- 1009 • **Gary H. Lyman, MD, MPH, FASCO, FRCP**; Jerome J. Graber MD, MPH; Petros Grivas, MD, PhD; Elizabeth T.
1010 Loggers, MD, PhD; Ryan C. Lynch, MD; Elizabeth S. Nakasone, MD, PhD; Michael T. Schweizer, MD; Lisa
1011 Tachiki, MD; Shaveta Vinayak, MD, MS; Michael J. Wagner, MD; Albert Yeh, MD (Fred Hutchinson Cancer
1012 Research Center/University of Washington/Seattle Cancer Care Alliance, Seattle, WA, USA)
- 1013 • **Sharad Goyal, MD; Minh-Phuong Huynh-Le, MD, MAS** (George Washington University, Washington, DC,
1014 USA)
- 1015 • **Lori J. Rosenstein, MD** (Gundersen Health System, WI, USA)
- 1016 • **Peter Paul Yu, MD, FACP, FASCO**; Jessica M. Clement, MD; Ahmad Daher, MD; Mark E. Dailey, MD; Rawad
1017 Elias, MD; Asha Jayaraj, MD; Emily Hsu, MD; Alvaro G. Menendez, MD; Oscar K. Serrano, MD, MBA, FACS
1018 (Hartford HealthCare Cancer Institute, Hartford, CT, USA)
- 1019 • **Clara Hwang, MD**; Shirish M. Gadgeel, MD; Sunny R K Singh, MD (Henry Ford Cancer Institute, Henry Ford
1020 Hospital, Detroit, MI, USA)

- 1021 • **Melissa K. Accordino, MD, MS**; Divaya Bhutani, MD; Jessica E. Hawley, MD; Dawn Hershman, MD, MS,
1022 FASCO; Gary K. Schwartz, MD (Herbert Irving Comprehensive Cancer Center at Columbia University, New York,
1023 NY, USA)
- 1024 • **Daniel Y. Reuben, MD, MS**; Mariam Alexander, MD, PhD; Sara Matar, MD; Sarah Mushtaq, MD (Hollings
1025 Cancer Center at the Medical University of South Carolina, Charleston, SC, USA)
- 1026 • **Eric H. Bernicker, MD** (Houston Methodist Cancer Center, Houston, TX, USA)
- 1027 • **John F. Deeken, MD**; Danielle Shafer, DO (Inova Schar Cancer Institute, Fairfax, VA, USA)
- 1028 • **Mark A. Lewis, MD; Terence D. Rhodes, MD, PhD**; David M. Gill, MD; Clarke A. Low, MD (Intermountain
1029 Health Care, Salt Lake City, UT, USA)
- 1030 • **Sandeep H. Mashru, MD**; Abdul-Hai Mansoor, MD (Kaiser Permanente Northwest, OR/WA, USA)
- 1031 • **Brandon Hayes-Lattin, MD, FACP**; Aaron M. Cohen, MD, MS; Shannon McWeeney, PhD; Encida R. Nemecek,
1032 MD, MS, MBA; Staci P. Williamson, BS (Knight Cancer Institute at Oregon Health and Science University,
1033 Portland, OR, USA)
- 1034 • **Howard A. Zaren, MD, FACS**; Stephanie J. Smith, RN, MSN, OCN (Lewis Cancer & Research Pavilion @ St.
1035 Joseph's/Candler, Savannah, GA, USA)
- 1036 • **Gayathri Nagaraj, MD**; Mojtaba Akhtari, MD; Eric Lau, DO; Mark E. Reeves, MD, PhD (Loma Linda University
1037 Cancer Center, Loma Linda, CA, USA)
- 1038 • **Stephanie Berg, DO**; Natalie Knox (Loyola University Medical Center, Maywood, IL, USA)
- 1039 • **Firas H. Wehbe, MD, PhD**; Jessica Altman, MD; Michael Gurley, BA; Mary F. Mulcahy, MD (Lurie Cancer
1040 Center at Northwestern University, Chicago, IL, USA)
- 1041 • **Eric B. Durbin, DrPH, MS** (Markey Cancer Center at the University of Kentucky, Lexington, KY, USA)
- 1042 • **Amit A. Kulkarni, MD**; Heather H. Nelson, PhD, MPH; Zohar Sachs, MD, PhD (Masonic Cancer Center at the
1043 University of Minnesota, Minneapolis, MN, USA)
- 1044 • **Rachel P. Rosovsky, MD, MPH; Kerry L. Reynolds, MD**; Aditya Bardia, MD; Genevieve Boland, MD, PhD,
1045 FACS; Justin F. Gainor, MD; Leyre Zubiri, MD, PhD (Massachusetts General Hospital Cancer Center, Boston, MA,
1046 USA)
- 1047 • **Thorvardur R. Halfdanarson, MD**; Tanios S. Bekaii-Saab, MD, FACP; Aakash Desai, MD, MPH; Surbhi Shah,
1048 MD; Zhuoer Xie, MD, MS (Mayo Clinic, AZ/FL/MN, USA) (Mayo Clinic, AZ/FL/MN, USA)
- 1049 • **Ruben A. Mesa, MD, FACP**; Mark Bonnen, MD; Daruka Mahadevan, MD, PhD; Amelie G. Ramirez, DrPH,
1050 MPH; Mary Salazar, DNP, MSN, RN, ANP-BC; Dimpy P. Shah, MD, PhD; Pankil K. Shah, MD, MSPH (Mays
1051 Cancer Center at UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA)
- 1052 • **Gregory J. Riely, MD, PhD; Elizabeth V. Robilotti MD, MPH**; Rimma Belenkaya, MA, MS; John Philip, MS
1053 (Memorial Sloan Kettering Cancer Center, New York, NY, USA)
- 1054 • **Bryan Faller, MD** (Missouri Baptist Medical Center, St. Louis, MO, USA)
- 1055 • **Rana R. McKay, MD**; Archana Ajmera, MSN, ANP-BC, AOCNP; Sharon S. Brouha, MD, MPH; Angelo Cabal,
1056 BS; Sharon Choi, MD, PhD; Albert Hsiao, MD, PhD; Jun Yang Jiang, MD; Seth Kligerman, MD; Taylor K.
1057 Nonato; Erin G. Reid, MD (Moores Comprehensive Cancer Center at the University of California, San Diego, La
1058 Jolla, CA, USA)
- 1059 • **Lisa B. Weissmann, MD**; Chinmay Jani, MD; Carey C. Thomson, MD, FCCP, MPH (Mount Auburn Hospital,
1060 Cambridge, MA, USA)
- 1061 • **Jeanna Knoble, MD**; Mary Grace Glace, RN; Cameron Rink, PhD, MBA; Karen Stauffer, RN; Rosemary Zacks,
1062 RN (Mount Carmel Health System, Columbus, OH, USA)
- 1063 • **Sibel Blau, MD** (Northwest Medical Specialties, Tacoma, WA, USA)
- 1064 • **Daniel G. Stover, MD**; Daniel Addison, MD; James L. Chen, MD; Margaret E. Gatti-Mays, MD; Sachin R. Jhavar,
1065 MD; Vidhya Karivedu, MBBS; Joshua D. Palmer, MD; Sarah Wall, MD; Nicole O. Williams, MD (The Ohio State
1066 University Comprehensive Cancer Center, Columbus, OH, USA)
- 1067 • **Monika Joshi, MD, MRCP**; Hyma V. Polimera, MD; Lauren D. Pomerantz; Marc A. Rovito, MD, FACP (Penn
1068 State Health/Penn State Cancer Institute/St. Joseph Cancer Center, PA, USA)
- 1069 • **Elizabeth A. Griffiths, MD**; Amro Elshoury, MBBCh (Roswell Park Comprehensive Cancer Center, Buffalo, NY,
1070 USA)
- 1071 • **Salma K. Jabbour, MD**; Christian F. Misdary, MD; Mansi R. Shah, MD (Rutgers Cancer Institute of New Jersey at
1072 Rutgers Biomedical and Health Sciences, New Brunswick, NJ, USA)
- 1073 • **Babar Bashir, MD, MS**; Christopher McNair, PhD; Sana Z. Mahmood, BA, BS; Vasil Mico, BS; Andrea Verghese
1074 Rivera, MD (Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA)

- 1075 • **Sumit A. Shah, MD, MPH**; Elwyn C. Cabebe, MD; Michael J. Glover, MD; Alok Kumar Jha, PhD; Ali Raza Khaki,
1076 MD; Lidia Schapira, MD, FASCO; Julie Tsu-Yu Wu, MD, PhD (Stanford Cancer Institute at Stanford University,
1077 Palo Alto, CA, USA)
- 1078 • **Suki Subbiah, MD** (Stanley S. Scott Cancer Center at LSU Health Sciences Center, New Orleans, LA, USA)
- 1079 • **Daniel B. Flora, MD, PharmD**; Goetz Kloecker, MD; Barbara B. Logan, MS; Chaitanya Mandapakala, MD (St.
1080 Elizabeth Healthcare, Edgewood, KY, USA)
- 1081 • **Gilberto de Lima Lopes Jr., MD, MBA, FAMS, FASCO** (Sylvester Comprehensive Cancer Center at the
1082 University of Miami Miller School of Medicine, Miami, FL, USA)
- 1083 • **Karen Russell, MD, FACP**; Brittany Stith, RN, BSN, OCN, CCRP (Tallahassee Memorial Healthcare, Tallahassee,
1084 FL, USA)
- 1085 • **Natasha C. Edwin, MD**; Melissa Smits, APC (ThedaCare Cancer Care, Appleton, WI, USA)
- 1086 • **David D. Chism, MD**; Susie Owenby, RN, CCRP (Thompson Cancer Survival Center, Knoxville, TN, USA)
- 1087 • **Deborah B. Doroshow, MD, PhD**; Matthew D. Galsky, MD; Michael Wotman, MD (Tisch Cancer Institute at the
1088 Icahn School of Medicine at Mount Sinai, New York, NY, USA)
- 1089 • **Julie C. Fu, MD**; Alyson Fazio, APRN-BC; Kathryn E. Huber, MD; Mark H. Sueyoshi, MD (Tufts Medical Center
1090 Cancer Center, Boston and Stoneham, MA, USA)
- 1091 • **Jonathan Riess, MD, MS**; Kanishka G. Patel, MD (UC Davis Comprehensive Cancer Center at the University of
1092 California at Davis, CA, USA)
- 1093 • **Vadim S. Koshkin, MD**; Hala T. Borno, MD; Daniel H. Kwon, MD; Eric J. Small, MD; Sylvia Zhang, MS (UCSF
1094 Helen Diller Family Comprehensive Cancer Center at the University of California at San Francisco, CA, USA)
- 1095 • **Samuel M. Rubinstein, MD; William A. Wood, MD, MPH**; Christopher Jensen, MD (UNC Lineberger
1096 Comprehensive Cancer Center, Chapel Hill, NC, USA)
- 1097 • **Trisha M. Wise-Draper, MD, PhD**; Syed A. Ahmad, MD, FACS; Punita Grover, MD; Shuchi Gulati, MD; Jordan
1098 Kharofa, MD; Tahir Latif, MBBS, MBA; Michelle Marcum, MS; Hira G. Shaikh, MD (University of Cincinnati
1099 Cancer Center, Cincinnati, OH, USA)
- 1100 • **Daniel W. Bowles, MD**; Christopher L. Geiger, MD (University of Colorado Cancer Center, Aurora, CO, USA)
- 1101 • **Merry-Jennifer Markham, MD, FACP, FASCO**; Atlantis D. Russ, MD, PhD; Haneen Saker, MD (University of
1102 Florida Health Cancer Center, Gainesville, FL, USA)
- 1103 • **Jared D. Acoba, MD**; Young Soo Rho, MD, CM (University of Hawai'i Cancer Center, Honolulu, HI, USA)
- 1104 • **Lawrence E. Feldman, MD; Kent F. Hoskins, MD**; Gerald Gantt Jr., MD; Li C. Liu, PhD; Mahir Khan, MD;
1105 Ryan H. Nguyen, DO; Mary Pasquinelli, APN, DNP; Candice Schwartz, MD; Neeta K. Venepalli, MD, MBA
1106 (University of Illinois Hospital & Health Sciences System, Chicago, IL, USA)
- 1107 • **Praveen Vikas, MD** (University of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA)
- 1108 • **Elizabeth Wulff-Burchfield, MD**; Anup Kasi MD, MPH (The University of Kansas Cancer Center, Kansas City,
1109 KS, USA)
- 1110 • **Christopher R. Friese, PhD, RN, AOCN, FAAN; Leslie A. Fecher, MD** (University of Michigan Rogel Cancer
1111 Center, Ann Arbor, MI, USA)
- 1112 • **Blanche H. Mavromatis, MD**; Ragneel R. Bijjula, MD; Qamar U. Zaman, MD (UPMC Western Maryland,
1113 Cumberland, MD, USA)
- 1114 • **Jeremy L. Warner, MD, MS, FAMIA, FASCO**; Alaina J. Brown, MD, MPH; Alicia Beeghly-Fadiel, PhD; Alex
1115 Cheng, PhD; Sarah Croessmann, PhD; Elizabeth J. Davis, MD; Stephany N. Duda, PhD, MS; Kyle T. Enriquez,
1116 MSc BS; Benjamin French, PhD; Erin A. Gillaspie, MD, MPH; Daniel Hausrath, MD; Cassandra Hennessy, MS;
1117 Chih-Yuan Hsu, PhD; Douglas B. Johnson, MD, MSCI; Xuanyi Li, BA; Sanjay Mishra, MS, PhD; Sonya A. Reid,
1118 MD, MPH; Brian I. Rini, MD, FACP, FASCO; Yu Shyr, PhD; David A. Slosky, MD; Carmen C. Solorzano, MD,
1119 FACS; Tianyi Sun, MS; Matthew D. Tucker, MD; Karen Vega-Luna, MA; Lucy L. Wang, BA (Vanderbilt-Ingram
1120 Cancer Center at Vanderbilt University Medical Center, Nashville, TN, USA)
- 1121 • **David M. Aboulafia, MD**; Brett A. Schroeder, MD (Virginia Mason Cancer Institute, Seattle, WA, USA)
- 1122 • **Matthew Puc, MD**; Theresa M. Carducci, MSN, RN, CCRP; Karen J. Goldsmith, BSN, RN; Susan Van Loon, RN,
1123 CTR, CCRP (Virtua Health, Marlton, NJ, USA)
- 1124 • **Umit Topaloglu, PhD, FAMIA**; Saif I. Alimohamed, MD (Wake Forest Baptist Comprehensive Cancer Center,
1125 Winston-Salem, NC, USA)
- 1126 • **Robert L. Rice, MD, PhD** (WellSpan Health, York, PA, USA)
- 1127 • **Prakash Peddi, MD; Lane R. Rosen, MD**; Briana Barrow McCollough, BSc, CCRP (Willis-Knighton Cancer
1128 Center, Shreveport, LA, USA)

- 1129
- 1130
- 1131
- 1132
- 1133
- 1134
- **Mehmet A. Bilen, MD**; Cecilia A. Castellano; Deepak Ravindranathan, MD, MS (Winship Cancer Institute of Emory University, Atlanta, GA, USA)
 - **Navid Hafez, MD, MPH**; Roy Herbst, MD, PhD; Patricia LoRusso, DO, PhD; Maryam B. Lustberg, MD, MPH; Tyler Masters, MS; Catherine Stratton, BA (Yale Cancer Center at Yale University School of Medicine, New Haven, CT, USA) (Yale Cancer Center at Yale University School of Medicine, New Haven, CT, USA)